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DNA methylation is one of the major epigenetic processes which is crucially involved 
in orchestrating gene regulation primarily by repression of gene expression. It has 
been shown that DNA methylation plays an important role in controlling functional 
programs of embryonic and tissue stem cells. As altered DNA methylation patterns 
are a hallmark of cancer, we hypothesized that DNA methylation might be equally 
important for cell fate determination of cancer stem/initiating cells (CSC). To test this, 
I analyzed a genetic knockdown mouse model of the main somatic DNA methyltrans-
ferase Dnmt1 in the context of three different oncogene driven leukemia models. 
A bilinear B-lymphoid/myeloid leukemia model was utilized to test the role of DNA 
methylation in lineage decision processes of a bi-potential leukemia stem/initiating 
cell (LSC). Whereas hypomethylated LSCs were capable to form a myeloid leukemia, 
no B-lymphoid blasts were given rise to by these cells. Moreover, failure of hypo-
methylated cells to develop T-cell lymphomas in a Notch1-based leukemia model 
demonstrated their profound lack of T-lineage commitment capacities. These data 
suggest that lineage fate choices of LSCs are determined by the level of DNA meth-
ylation. Furthermore, the effect of hypomethylation on the acquisition and mainte-
nance of leukemia self-renewal potential was investigated in a myeloid leukemia 
model. Both in vitro and in vivo assays revealed a severely reduced self-renewal 
potential of transformed Dnmt1 knockdown cells. This was illustrated by a more than 
10-fold reduction of functional LSCs in hypomethylated leukemias. However, con-
trasting the drastic cell-intrinsic impairments of LSC function by reduced DNA 
methylation, leukemia development was found to be unaffected by hypomethylated 
bone marrow stroma. Mechanistically, treatment of cell lines with a demethylating 
drug led to enhanced expression of differentiation factors due to loss of methylation 
mediated gene silencing. This was followed by inhibition of leukemia cell growth, thus 
providing a potential mechanism for impaired functions of hypomethylated leukemias.  
Collectively, this thesis revealed a critical role for DNA methylation levels in malignant 
self-renewal and lineage fate choices. These new insights into epigenetic regulation 
of CSCs suggest that epigenetic therapy displays a potential treatment concept 
specifically targeting CSCs. 




DNA Methylierung ist ein zentraler epigenetischer Prozess, welcher, hauptsächlich 
durch Repression von Genexpression, entscheidend an der Organisation von Genre-
gulation beteiligt ist. Dieser Vorgang ist wichtig für die Funktion sowohl von em-
bryonalen als auch von Gewebs-Stammzellen. Krebszellen weisen häufig veränderte 
DNA Methylierungsmuster auf, was auf eine ähnlich wesentliche Rolle der DNA Me-
thylierung bei Zellschicksalsentscheidungen von Krebsstammzellen hindeutet. Diese 
These wurde hier mit Hilfe eines Mausmodells mit verringerter Expression der DNA 
Methyltransferase Dnmt1 anhand drei verschiedener Leukämiemodelle untersucht. 
In einem bi-linearen B-lymphatischen/myeloischen Leukämiemodell konnte gezeigt 
werden, dass hypomethylierte, bi-potente leukämieinitiierende (Stamm-)zellen (LSZ) 
myeloische Krebszellen hervorbringen, allerdings nicht zur Bildung von B-lym-
phatischen Leukämiezellen befähigt sind. Darüber hinaus konnte in einem T-Zell-
spezifischen Leukämiemodell gezeigt werden, dass reduzierte Dnmt1 Expression 
nicht mit der Bildung von T-Zelllymphomen vereinbar ist. Detaillierte Analysen eines 
myeloischen Leukämiemodells ergaben, dass LSZs mit verringertem DNA Methy-
lierungsgrad ein vermindertes Selbsterneuerungspotenzial aufweisen, was an einer 
um mehr als zehnfach geringeren Zahl funktioneller LSZs deutlich wurde. Im 
Gegensatz zu den starken Einschränkungen im Funktionsrepertoire von LSZs durch 
verminderte Dnmt1 Expression, hatten hypomethylierte Knochenmarks-Stromazellen 
keinen Effekt auf die Entwicklung von Leukämien. Außerdem konnte gezeigt werden, 
dass Behandlung verschiedener leukämischer Zellen mit demethylierenden Agenzien 
zu einer teilweisen Aufhebung methylierungsvermittelter Genrepression führte. Die 
dadurch verstärkte Expression von Differenzierungsfaktoren verminderte das 
Leukämiewachstum, was einen möglichen Erklärungsansatz für das eingeschränkte 
Potenzial hypomethylierter Leukämien darstellt.  
Die Ergebnisse dieser Arbeit demonstrieren eine zentrale Rolle der DNA 
Methylierung für die Selbsterneuerung und Linienwahl von LSZs, und erlauben somit 
neue Einblicke in die epigenetische Regulation von Krebsstammzellen. Diese 
Erkenntnisse implizieren, dass Krebsstammzellen möglicherweise ein geeignetes 
Ziel für epigenetische Therapieansätze darstellen. 
Schlagwörter: DNA Methylierung, Krebsstammzelle, Selbsterneuerung, Linienwahl




In 2001 the sequencing of the human genome had been essentially completed, 
displaying a milestone in molecular biological research [Lander, et al., 2001; 
McPherson, et al., 2001]. Even though the genome is the ultimate template of our 
hereditary, today’s understanding is that the knowledge of the primary DNA 
sequence itself is merely the foundation for understanding how the genetic program 
is read and implemented. Research in the last years has revealed increasing 
importance of information which is “outside” or “above” genetics, or in another word 
“epigenetic”. The term epigenetics was coined by Conrad H. Waddington in 1942 as 
a fusion of the words genetics and epigenesis describing “the branch of biology 
which studies the causal interactions between genes and their products, which bring 
the phenotype into being” [Waddington, 1942]. Epigenetics is the study of those 
processes by which the genetic information, defined as genotype, interacts with the 
environment in order to produce its observed characteristics, defined as phenotype. 
This offers a conceptual model of how the phenotype is produced through the 
interaction of genes with their surrounding without any changes in the underlying 
DNA sequence, consequently representing a bridge between genotype and 
phenotype. Over time, a variety of epigenetic processes has been described, like 
imprinting of maternal or paternal genes [McGrath and Solter, 1984; Surani, et al., 
1984], X chromosome inactivation [Lyon, 1961] or paramutation in maize [Brink, 
1958], which will not be addressed in more detail here, as they are out of the scope 
of this work. 
More important here, cellular differentiation processes are regarded as epigenetic 
phenomena. Even though cells of a multicellular organism share the same genetic 
instruction sets, a great diversity of cell types with very different terminal phenotypes 
is generated from the originally totipotent cell. During this development the cell 
undergoes changes in its epigenetic state, a fact that has been famously illustrated 
as the epigenetic landscape by Conrad H. Waddington in 1957 [Waddington, 1957]. 
The epigenetic landscape (Figure 1A) is a metaphor displaying the process of 
cellular decision-making, with a marble (representing a cell) rolling down a hill into 
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one of several valleys. The cell can follow different permitted trajectories, finally 
reaching its destination at the bottom of a certain valley, reflecting a terminally 
differentiated state. From today’s point of view, we know that at each point in this 
slope the cell has a specific epigenetic state which is causal for the cell’s gene 
expression profile. Thus, the epigenetic information of a cell (epigenome) displays a 
stable and heritable, yet changeable, layer of information which instructs cell fates by 
defining the activity of genes. This is achieved by epigenetic alterations which 
regulate both chromatin structure and the accessibility of the DNA. Our current 
knowledge about such epigenetic modifications and players led to an updated 
version of Waddington’s landscape transforming it into a pinball map (Figure 1B; 
[Goldberg, et al., 2007]. Countless mechanisms involving effectors, players and 
presenters have been identified in years of intensive research, some of which will be 
introduced in the following section. 
A B
 
Figure 1: Waddington’s epigenetic landscape evolving to a pinball map 
A) In the epigenetic landscape, a cell, represented by a marble, faces a number of branching points 
on it way down the hill of cellular development, eventually reaching one of the valleys, representing 
potential phenotypic endpoints [Waddington, 1957]. B) In this modern version of Waddington’s picture 
the landscape has transformed into a pinball map. Many structures and actors push and redirect the 
pinball (cell) and guide it along the correct way to the desired endpoint. Illustrated by Sue Ann Fung-
Ho [Goldberg, et al., 2007]. 
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At large, epigenetic modifications fall in two main categories: DNA methylation and 
histone tail modifications. The nature of those modifications defines the overall 
structure of the chromatin - the complex of DNA and its associated proteins. The 
state of chromatin architecture, in turn, determines the accessibility to the underlying 
DNA, consequently regulating transcriptional activity. 
At the heart of chromatin structure conserved histone proteins act as building blocks 
for packaging DNA into nucleosomal repeats [Strahl and Allis, 2000]. The 
unstructured tails of the histone proteins can be equipped with different kinds of 
modifications, such as acetylation, methylation, phosphorylation or ubiquitination, 
which are placed at specific positions of the amino-terminal tail. For example, 
whereas methylation of histone H3 lysine 4 (H3K4) is generally associated with trans-
cribed chromatin, methylation of H3K9 or H3K27 usually correlates with repression 
[Bernstein, et al., 2007]. Histone modifications are added by catalytic enzymes which 
serve as writers, e.g. the histone methyltransferase SUV39H1, and the mark is 
recognized by a reader or an effector (like HP1 proteins), which launches the 
biological implementation at this specific locus [Lachner, et al., 2001]. The sum of all 
histone modifications is thought to be deciphered as a histone code installing an 
epigenetic state which determines the actual readout of the genetic information of a 
certain locus through activation or silencing [Jenuwein and Allis, 2001].  
Apart from the just recently discovered 5-Hydroxymethylcytosine [Kriaucionis and 
Heintz, 2009; Tahiliani, et al., 2009], DNA methylation is the only known covalent 
modification of DNA in mammals As it is a key aspect of this thesis it will therefore be 
introduced more thoroughly in the next chapter. 
1.2 DNA methylation 
DNA methylation describes the addition of methyl groups to the DNA and is found 
both in prokaryotic and eukaryotic organisms, including fungi, plants, non-vertebrates 
and vertebrates. Some species are devoid, or almost completely devoid of DNA 
methylation, like Caenorhabditis elegans or Drosophila melanogaster [Bird, 2002]. In 
vertebrates DNA methylation occurs almost exclusively at cytosine residues in the 
context of a CpG dinucleotide. As depicted in Figure 2, DNA methyltransferases 
(DNMTs) catalyze the transfer of a methyl group from S-adenosylmethionine (SAM) 
to the C5 position of a cytosine. 






Figure 2: Cytosine methylation catalyzed by DNA methyltransferase (DNMT) 
A methyl group (-CH3) is added to the carbon-5 position of a cytosine residue of the DNA. S–
adenosylmethionine serves as methyl group donor. The reaction is catalyzed by DNA methyltrans-
ferases (DNMTs). 
Cytosine residues are hotspots of base substitution mutations as they are vulnerable 
to spontaneous deamination. Deamination of an unmethylated cytosine yields uracil, 
a base which is removed from the DNA sequence by the enzyme uracil glycosylase 
[Lindahl, 1974]. In contrast, deamination of 5–methylcytosine produces thymine, a 
normal DNA base, which is hence not removed by any DNA repair machinery 
eventually causing a G–C to A–T pair transition [Coulondre, et al., 1978; Lindahl, 
1982]. As an evolutionary consequence, this CpG hypermutability caused an 
approximately 5-fold underrepresentation of this dinucleotide throughout the genome 
[Bird, 1980; Lander, et al., 2001]. 55-90 % of CpGs in the vertebrate genome are 
methylated and methylation is mainly found in transposable elements and 
endogenous retroviruses [Bird, et al., 1985; Yoder, et al., 1997b]. However, 
unmethylated CpG-rich regions are found in the genome: In these so called CpG 
islands CpG sites occur at the frequency expected by base composition and they are 
primarily found at the 5’ ends of genes [Bird, 1986; Gardiner-Garden and Frommer, 
1987]. DNA methylation was shown to be involved in multiple functions like 
transcriptional silencing, heterochromatin formation, genomic stability, silencing of 
endogenous retroviruses, genomic imprinting and X chromosome inactivation [Goll 
and Bestor, 2005; Jaenisch, 1997]. Before discussing the biological functions of DNA 
methylation in respect to its role in development and disease in the chapters 1.3 to 
1.5, the following part will introduce the actors involved in the establishment and 
translation of the methylation pattern. 
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1.2.1 Establishment and maintenance of the methylation system 
During mammalian development, the DNA methylation pattern is subject to dramatic 
changes which are managed in a highly regulated process [Monk, et al., 1987]. 
During cleavage, first, DNA methylation is actively stripped off the paternal genome, 
followed by passive erasure of maternal methylation marks in the following cell 
divisions [Li, 2002; Mayer, et al., 2000; Oswald, et al., 2000; Rougier, et al., 1998]. 
Between implantation and gastrulation a wave of global methylation reestablishes the 
overall methylation pattern which is maintained in the somatic cells throughout life 
[Jaenisch, 1997]. These facts imply the existence of two general classes of DNA 
(cytosine-5) methyltransferases (DNMTs), a prediction which had already been made 
35 years ago [Holliday and Pugh, 1975; Riggs, 1975]: A class of de novo enzymes 
responsible for the establishment of methylation patterns at specific sequences in 
early development and a group of maintenance enzymes preserving the methylation 
pattern during cell division. Up to date, five mammalian DNMTs are known which can 
be placed in three different groups based on their structural and functional 
characteristics (Figure 3, [Goll and Bestor, 2005]).  
 
Figure 3: Murine DNMT family members 
Protein length of the five DNMTs is indicated on the right side (aa, number of amino acids). The 
regulatory N-terminal domain contains a number of functional motifs: a nuclear localization signal 
(NLS), a sequence required association with the replication foci, a cysteine-rich zinc finger DNA-
binding motif and bromo-adjacent homology (BAH) domains, a protein-protein interaction module 
targeting DNMT to the replication foci. The PWWP tetra-peptide is essential for DNMT binding to 
chromatin. The C-terminal part harbors the catalytic methyltransferase domain with six conserved 
motifs [Goll and Bestor, 2005] 
DNMT2 was assigned to the DNMT family due to structural homologies, yet it was 
found that it does not posses any DNA methyltransferase activity. Instead, it was 
discovered to be an RNA methyltransferase, methylating cytosine 38 in the anticodon 
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loop of tRNAs [Goll, et al., 2006; Schaefer, et al., 2010; Yoder and Bestor, 1998]. 
Due to DNMT2 actually being falsely categorized as a DNMT, it will not be discussed 
any further in this chapter. The maintenance methyltransferase DNMT1 and the 
DNMT3 family, responsible for de novo methylation, will be introduced in the 
following section. 
1.2.1.1 DNMT1 
The gene encoding the 1620 amino acids long protein DNMT1 is located on 
chromosome 9 of the mouse genome and displays the first eukaryotic methyltrans-
ferase to be cloned and purified [Bestor, et al., 1988]. A 5- to 30-fold substrate-
preference for hemi-methylated DNA compared to un-methylated DNA confirmed its 
function as maintenance methyltransferase [Gruenbaum, et al., 1982; Yoder, et al., 
1997a]. During the S-phase of the cell cycle DNMT1 is recruited to the regions of 
active DNA replication, the replication foci, mediated by sequence motifs in the N-
terminal part of DNMT1. A specific motif interacts with the proliferating-cell-nuclear-
antigen (PCNA), the DNA clamp protein, which is located at the replication forks 
during DNA replication [Chuang, et al., 1997; Leonhardt, et al., 1992]. Besides 
PCNA, several other factors have been shown to interact with DNMT1 and help its 
recruitment to the replication forks. For example, UHRF1 (ubiquitin-like, containing 
PHD and RING finger domains 1) appears to tether DNMT1 to the chromatin by 
directly interacting with DNMT1. The SRA (SET and RING associated) domain of 
UHRF1 was shown to strongly preferentially bind to hemimethylated DNA, being at 
least in part responsible for DNMT1’s specificity for its physiological substrate 
[Bostick, et al., 2007].  
The methyltransferase domain of DNMT1, harbored at the C-terminal part of the 
protein, catalyzes the transfer of a methyl group to the nascent DNA strand if a 
methyl group is present on the parallel position on the parental strand [Gruenbaum, 
et al., 1982]. Thus, DNMT1 passes on the epigenetic information during cell 
generations by faithfully copying the parental strand methylation pattern onto the 
progeny DNA strand. 
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1.2.1.2 The DNMT3 family 
In 1996, En Li’s group generated a null mutant of the so far only known DNA 
methyltransferase, DNMT1, and the mutant embryonic stem (ES) cells still showed 
low but stable levels of methyltransferase activity, suggesting the existence of a 
second mammalian methyltransferase [Lei, et al., 1996]. Two years later, the closely 
related DNMT3a and DNMT3b were identified and found to be crucial for de novo 
methylation but not to be involved in the maintenance of DNA methylation [Okano, et 
al., 1999; Okano, et al., 1998]. 
Next to DNMT3a and DNMT3b, the DNMT3 family comprises a third member: the 
DNMT3-like protein, DNMT3L [Aapola, et al., 2000]. Even though Dnmt3L is devoid 
of enzymatic methyltransferase activity, it was shown to be essential for the 
establishment of maternal genomic imprints by interacting with Dnmt3a [Bourc'his, et 
al., 2001; Hata, et al., 2002; Jia, et al., 2007]. Furthermore, recent findings indicated 
an interesting link of DNA methylation to histone modifications. DNMT3L was found 
to bind unmethylated, but not methylated, histone 3 lysine 4 (H3K4), suggesting a 
specific recruitment of de novo methyltransferases to unmethylated H3K4, which 
might display a mechanism for transmitting non-inheritable histone marks by means 
of heritable DNA methylation [Ooi, et al., 2007]. 
Gene silencing at specific loci has been shown not to be exclusively exerted by the 
DNA methyltransferases, but rather is an interplay between different epigenetic 
silencing mechanisms, which ensures a reliable shutdown of promoter sequences. 
Even though it is still largely unclear which mechanisms orchestrate the interactions 
between epigenetic processes, some connections between epigenetic factors have 
been uncovered in the last years, starting to shed some light on the epigenetic 
networks. In 2006, DNMT1, DNMT3a and 3b were all shown to interact with the 
Polycomb group (PcG) protein EZH2 (Enhacer of Zeste homolog 2), which functions 
as a histone methyltransferase in transcriptional repression. This interaction serves 
as a mechanism to dictate site specific DNA methylation at certain loci guaranteeing 
proper establishment and maintenance of gene silencing [Vire, et al., 2006]. One 
year later, the connection between the H3K9 methyltransferase G9a and DNMT1 
was uncovered providing a mechanism by which DNA methylation activity is recruited 
to specific targets [Smallwood, et al., 2007]. This further emphasizes the 
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interdependency of different processes to allow epigenetic repression in a targeted 
fashion.  
1.2.2 Translating DNA methylation marks 
DNA methylation is usually associated with transcriptionally silent chromatin. But how 
does DNA methylation interfere with transcription? Two models of repression can be 
envisaged for this process, both of which have been shown to be biologically relevant 
(Figure 4, [Bird, 2002]). 
 
Figure 4: Transcriptional repression mechanisms by DNA methylation 
Two basic models for transcriptional silencing by DNA methylation have evolved: In the first, DNA 
methylation (red circles) can directly repress transcription by preventing transcription factors from 
binding to their cognate DNA sequences. In the second model, transcriptional inhibition is achieved by 
specialized Methyl-CpG-binding proteins (MBPs), like MBD1-3, MeCP2 and Kaiso, which recruit 
different chromatin modifying repressor complexes [Bird, 2002]. 
In the first model, transcriptional activators are directly prevented from binding to their 
cognate sequences in regulatory DNA elements. Many factors are known to bind to 
CpG-containing sequences and some of them fail to bind the DNA if the cytosine 
residue is methylated. One of the most prominent examples for this mode of action is 
the reduced binding of the oncoprotein c-Myc to E-box sequence motifs by methyla-
ting the CpG within this recognition site [Prendergast and Ziff, 1991]. More recently, 
the chromatin organizer CTCF was shown to bind in a methylation sensitive fashion 
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to the non-methylated maternal allele of H19/Igf2 locus in mouse. Thus, CTCF can 
exert its insulating function, meaning it is shielding enhancer elements, to specifically 
silence the maternal copy of the Igf2 gene, whereas the methylated paternal copy 
prevents CTCF binding, consequently allowing surrounding enhancers to drive Igf2 
expression [Bell and Felsenfeld, 2000; Hark, et al., 2000; Holmgren, et al., 2001; 
Szabo, et al., 2000]. 
The second repression mechanism involves specialized proteins, so called Methyl-
CpG-binding proteins (MBPs), which bind to methylated CpG sites and mediate 
silencing of gene expression by targeting co-repressors to the respective loci. The 
family of MBPs comprises six members (MBP1-4, MeCP2 and Kaiso) and all but 
MBP3 and Kaiso possess a conserved Methyl-CpG-binding domain (MDB) to bind 
methylated DNA [Hendrich and Bird, 1998]. Bound MBPs recruit repressor 
complexes with chromatin remodeling or modifying properties, like MeCP2 recruiting 
a histone deacetylases (HDACs) together with the co-repressor Sin3 [Jones, et al., 
1998; Nan, et al., 1998]. Repressing mechanisms via MBP1 are not entirely clear yet, 
but MBP1 was shown to be associated with H3K9 histone methyltransferase 
SETDB1 [Sarraf and Stancheva, 2004]. Another example for a repressor complex is 
MeCP1, which comprises MBP2, MBP3, the HDAC complex NuRD and Mi-2, a 
chromatin remodeling protein from the SWI2/SNF2 family [Wade, et al., 1999; Zhang, 
et al., 1999]. Finally, Kaiso, which recognizes methyl-CpG with its zinc-finger domain, 
is known to mediate transcriptional silencing by recruiting the HDAC-containing co-
repressor complex N-CoR [Yoon, et al., 2003]. 
More recent studies have uncovered a further mechanism by which transcription is 
suppressed by DNA methylation. In this case, instead of inhibiting transcriptional 
initiation by promoter methylation, transcriptional elongation efficiency is decreased 
by reducing Pol ll processivity through methylation of intragenic CpGs [Lorincz, et al., 
2004]. 
1.2.3 Removal of DNA methylation marks 
Even though DNA methylation is a stable epigenetic mark, it is yet known to be 
reversible, which raises the question about processes erasing the methylation marks 
from cytosines. The most obvious solution is a passive loss of methylation during cell 
division, when the parental methylation mark is not copied to the daughter strand. 
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However, loss of DNA methylation in the male pronucleus of the zygote (see 1.2.1, 
page 10) occurs without cell division and corresponding DNA replication, suggesting 
an active removal, rather than a passive loss. The process of active demethylation in 
mammals is yet only poorly understood. One possible scenario would be the removal 
of the methyl group, which is unlikely as the carbon-carbon bond is thermodynami-
cally stable [Bird, 2002]. Furthermore, demethylation could be accomplished by a 
DNA repair-like process, such as base excision repair or nucleotide excision repair, 
but the role of these mechanisms in mammalian demethylation has been only 
insufficiently described [Wu and Zhang, 2010]. Recent studies suggested Gadd45a 
(growth arrest and DNA-damage-inducible protein 45 alpha) as a key regulator of 
active DNA demethylation through promoting DNA methylation [Barreto, et al., 2007]. 
Demethylation in plants, in contrast, is much better understood. Plants use DNA 
glycosylases, normally associated with DNA repair, to remove 5-methylcytosines and 
replace them with cytosines [Gong, et al., 2002]. However, in mammals and animals 
in general, factors acting as active demethylases have not yet been compellingly 
identified, leaving the question for active DNA demethylation mechanisms a topic of 
current research. 
1.3 DNA methylation in development and differentiation  
With DNA methylation being a crucial part in gene regulation, great research effort 
has been put into experimental studies aiming to uncover the role of DNA 
methylation in developmental and differentiation processes. For this purpose, DNA 
methyltransferase activity was manipulated experimentally by either directly targeting 
the genes encoding factors involved in DNA methylation processes or by pharma-
cological inhibition with demethylating reagents.  
Targeted ablation of methyltransferase genes in mouse models yielded crucial 
insights into the function of DNA methylation. Several mouse models using different 
knockout alleles of the Dnmt1 gene have been generated to examine the role of the 
maintenance methyltransferase in vivo. All knockout mice showed profound de-
methylation causing embryonic lethality between day 8.5 and 10.5 p.c. [Lei, et al., 
1996; Li, et al., 1993; Li, et al., 1992].  
Indispensability was also shown for the de novo methyltransferases Dnmt3a and 
Dnmt3b. While Dnmt3a-deficient mice survive to term, but are runted and die in early 
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adulthood with defects in the intestinal system and in spermatogenesis, Dnmt3b 
knockout mice die around day 14.5 of embryogenesis due to growth impairment and 
neural tube defects [Okano, et al., 1999]. Combined deficiency of Dnmt3a and 
Dnmt3b leads to even more severe defects than the single mutants with growth and 
morphogenesis arrest causing death around day 9.5 [Okano, et al., 1999]. Taken 
together, these studies showed that all Dnmt family members are indispensable for 
embryonic development and the severity of the observed phenotypes strongly under-
lines the importance of DNA methylation in early developmental processes. 
Besides the importance of DNA methylation in embryogenesis, a crucial role for this 
epigenetic process has also been shown in several somatic tissues. Due to the 
embryonic lethality caused by the deletion of Dnmt1, a conditional knockout allele 
(Dnmt1lox) was constructed, where the catalytic domain, harbored in exons 4 and 5, 
was flanked by loxP sites, allowing the inducible and cell-type specific deletion of 
Dnmt1 with the Cre/loxP system [Jackson-Grusby, et al., 2001; Sauer and 
Henderson, 1989]. Deletion of Dnmt1 in fibroblasts from homozygous Dnmt1lox mice 
with a Cre-recombinase expressing retrovirus led to severe demethylation, causing 
re-activation of silenced endogenous retroviral elements and dramatic changes in 
gene expression, finally leading to p53-dependent cell death. 
The adult brain exhibits higher levels of DNA methylation than any other tissue and 
DNA methylation levels were shown to undergo dynamic changes in perinatal stages, 
suggesting DNA methylation is involved in nervous system differentiation processes 
[Ono, et al., 1993; Tawa, et al., 1990; Wilson, et al., 1987]. Furthermore, neural 
differentiation can be blocked by the demethylating agent 5-azacytidine in an in vitro 
model [Persengiev and Kilpatrick, 1996].  
In clear contrast to the dependence of differentiated somatic cells on functional DNA 
methylation, undifferentiated embryonic stem (ES) cells can tolerate hypomethylation 
caused by inactivation of Dnmt1 or both Dnmt3a and Dnmt3b. Dnmt1 knockout ES 
cells, even though being strongly hypomethylated, are viable and grow without any 
limitations regarding their proliferative capacity if maintained in non-differentiation 
culture conditions [Lei, et al., 1996]. Similarly, combined deletion of Dnmt3a and 
Dnmt3b in ES cells did not have any effect on their viability and retained their stem 
cell characteristics. Even triple knockout ES cells, depleted of Dnmt1, Dnmt3a and 3b 
and consequently devoid of any CpG methylation, maintained stem cell charac-
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teristics, proliferation ability and normal chromosomal order [Tsumura, et al., 2006]. 
However, if any of the knockout ES cell lines was subjected to differentiation, either 
by using differentiation-driving culture conditions or by blastocyste injection, hypo-
methylated cells succumb to rapid cell death. This clear discrepancy between differ-
entiated cells and undifferentiated ES cells, raised the question as to whether adult 
somatic tissue stem cells are critically dependent on DNA methylation like their differ-
entiated counterparts, or can tolerate hypomethylation like ES cells. 
This issue has been tackled in various studies applying several differentiation 
models. Dnmt1, which is highly expressed in the mammalian brain [Goto, et al., 
1994], was specifically deleted in neural stem cells by combining Dnmt1lox mice with 
CamK-Cre transgenic mice, in which Cre expression is under the control of the 
neuronal camodulin-kinase II  (CamK). Dnmt1 deficiency resulted in hypomethylation 
of central nervous system stem-/precursor cells after cell division causing functional 
impairment and cell death [Fan, et al., 2001]. A more recent study applied a well-
defined in vitro differentiation system, which encompasses the differentiation from 
mouse ES cells via a committed progenitor stage to terminally differentiated glial cells 
[Bibel, et al., 2007]. DNA methylation analysis of promoter sequences of all three 
differentiation steps revealed a strong gain of CpG promoter methylation, underlining 
the importance of DNA methylation for somatic differentiation processes [Mohn, et 
al., 2008]. Furthermore, DNA methylation was shown to essentially control the regu-
lation between self-renewal- and differentiation–programs in epidermal tissue. 
Knockdown of Dnmt1 led to premature differentiation at the expense of self-renewal 
properties by lost repression of differentiation driving genes [Sen, et al., 2010]. Some 
of the most important scientific advances in the field of differentiation processes and 
stem cell biology have been made in studies of the hematopoietic system. The 
hematopoietic system itself and findings concerning genetic and epigenetic differ-
entiation processes which have been gathered studying this system will be intro-
duced in detail in the next chapter. 
1.4 Regulation of hematopoietic differentiation 
The hematopoietic system, encompassing the collectivity of blood cells and several 
other cell types, such as dendritic cells, neuron-attached microglia or bone resorbing 
osteoclasts, is a prototype experimental model system, which has been extensively 
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studied in the last decades. The importance of this model system is, at least in part, 
due to the many experimental advantages it offers. Hematopoietic cells are found in 
several organs, like bone marrow, spleen, lymph nodes, thymus, the peritoneal cavity 
and the peripheral blood, all of which can relatively easily be isolated, processed to 
single cell suspensions and used for experimental purposes. Development of 
fluorescence activated cell sorting (FACS) accompanied by the production of a 
constantly increasing number of fluorochrome-conjugated antibodies against cellular 
surface antigens, allowed a very precise characterization of hematopoietic cells. 
Additionally, this technique renders the possibility to separate distinct cell populations 
on the basis of their surface marker composition. Furthermore, differentiation 
processes of hematopoietic cells can be followed both in vitro, by providing specific 
differentiation conditions like cytokines or feeder cells, or in vivo, by transplantation of 
cells. Organ suspensions or sorted cell populations can be transferred by intravenous 
injection into recipient animals providing a precious tool to follow up cell fates within a 
chosen environment or experimental setting. 
1.4.1 The hematopoietic system 
Hematopoiesis describes the formation of blood cells and several other specified cell 
types mentioned earlier, a process requiring constant replenishment due to high 
turnover rates of cells. An estimated number of one trillion blood cells is formed in 
humans every day for the whole life [Ogawa, 1993]. This remarkable cell renewal 
process depends on hematopoietic stem cells (HSCs). The original pool of HSCs is 
formed during embryogenesis in a complex developmental process that involves 
several anatomical sites. In the mouse embryo, hematopoiesis occurs by day 8 
postconception in the yolk sac and the AGM (aorta-gonad-mesonephros region) 
followed by the fetal liver. At birth HSCs colonize the bone marrow where they reside 
in specialized niches, providing a lifelong resource for blood cell formation [Mikkola 
and Orkin, 2006]. HSCs display the apex of the differentiation hierarchy of the 
hematopoietic system (Figure 5). They are functionally defined at single-cell level by 
their ability to self-renew and to give rise to all lineages of blood cells [Becker, et al., 
1963; Jordan and Lemischka, 1990; Lemischka, et al., 1986; McCulloch and Till, 
1960]. These characteristics are founded in the HSCs’ capability to undergo 
asymmetric cell divisions, meaning that an individual HSC can give rise to 
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functionally not-equivalent paired daughter cells [Ema, et al., 2000; Takano, et al., 
2004]. Mouse transplantation experiments were applied to phenotypically identify the 
cell population which is equipped with these described characteristics, or, more 
practically, which is able to provide long-term reconstitution of a damaged bone 
marrow. These studies revealed that stem cell activity is harbored in a cell population 
described by the following cell surface marker combination: HSCs are negative for 
markers indicative of a specific lineage identity (so called lineage antigens; lin), and 
they are positive for both c-kit and sca-1 leading to their naming as LSK cells (lin-sca-
1+c-kit+). Differences in long-term reconstitution potential led to sub-division of the 
LSK compartment into long-term HSCs (LSK, CD34-Flt3-), short-term HSCs (LSK, 
CD34+Flt3-) and multipotent progenitors (LSK, CD34+Flt3+) [Adolfsson, et al., 2001; 
Osawa, et al., 1996; Yang, et al., 2005]. The latter population was shown to have 
significantly lost megakaryocytic potential, but exhibiting bias for lymphoid 
differentiation leading to its alternative designation as lymphoid primed multipotent 
progenitor (LMPP) [Adolfsson, et al., 2005] 
As described in Figure 5, hematopoietic differentiation consists of two major lineage 
pathways, the lymphoid an the myeloerythroid pathway. Differentiation via several 
lineage-specific precursor stages gives rise to a number of mature cell types, exerting 
a variety of essential physiological functions. Red blood cells and platelets are 
responsible for oxygen transport and blood clotting, respectively. All other cell types 
together build the immune system, with the myeloid macrophages and granulocytes 
composing the innate immune system, and lymphocytes, encompassing B cells, T 
cells and natural killer cells, forming the adaptive immune system. 
Taken together, HSCs give rise to progeny that progressively lose multipotency and 
self renewal capacity and become restricted to one lineage [Metcalf, 1999]. The com-
plexity of this system clearly calls for a tight regulation of cell fate choices in the 
course of hematopoietic differentiation. These regulatory networks have been subject 
to countless studies, revealing the involvement of genetic and epigenetic processes 
in the orchestration of cell fate decisions, both of which will be introduced in the 
following sections. 
 
























Figure 5: Scheme of the hematopoietic system 
Hematopoietic stem cells (HSC) with self-renewal capacities (red arrows) can be subdivided into long-
term and short-term HSC and multipotent progenitors (MPP). Differentiation follows two major 
pathways: the lymphoid branch starting with the common lymphoid progenitor (CLP) and the 
myeloerythroid branch developing from the common myeloid progenitor (CMP). Formation of mature 
blood cells is achieved via various lineage specific progenitor stages. NK, natural killer; GMP, 
granulocyte-macrophage precursor; MEP, megakaryocyte-erythrocyte precursor; MkP, megakaryocyte 
precursor; ErP, erythrocyte precursor. Adapted from [Reya, et al., 2001]. 
1.4.2 Genetic regulation of hematopoietic differentiation 
A great number of transcription factors have been identified to be involved in the 
pathway choice of multipotential cells in the hematopoietic system. For example, 
C/EBP  (CCAAT/enhancer binding protein ) and PU.1 were shown to belong to a 
group of master switches instructing myeloid differentiation [Rosenbauer and Tenen, 
2007]. Knockout mice for either factor display lack of distinct myeloid cell populations 
like granulocyte-macrophage progenitors (GMPs) and granulocytes (C/EBP –/–) or 
mature myeloid cells (PU.1–/–) [Iwasaki, et al., 2005; Zhang, et al., 1997]. 
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Furthermore, GATA-1, was shown to be indispensable for erythroid development as 
it functions as a major regulator on several erythroid-specific genes [Orkin, 1995; 
Simon, et al., 1992]. As to the lymphoid lineage, the factors EBF1, PAX5 and 
NOTCH-1 were proven to be essential for proper B-cell- and T-cell-development, 
respectively [Lin and Grosschedl, 1995; Nutt, et al., 1999; Radtke, et al., 1999]. 
Although differentiation appears to be a unidirectional process with subsequent steps 
of lineage commitment, experimental manipulation of transcription factor dosages 
have been shown to allow a cell to overcome a certain commitment and to chose an 
alternative fate. This was, for example, impressively shown by Thomas Graf’s group, 
who managed to convert mature B cells into macrophages by forced expression of 
the transcription factor C/EBP . 
Furthermore, it has been widely demonstrated that dysregulation of transcription 
factor expression can dramatically interfere with physiological differentiation path-
ways and might lead to cancer formation. For example, reduced expression of PU.1 
in HSCs and myeloid progenitors induced a differentiation block of the myeloid 
lineage leading to an aggressive form of acute myeloid leukemia (AML) in mice 
[Rosenbauer, et al., 2004]. On the other hand, enforced expression of NOTCH1 was 
shown to be a potent inducer of T-cell acute lymphoid leukemia (T-ALL) in mice and 
in fact over 50 % of human cases of T-ALL display activating mutations of NOTCH1 
[Aster, et al., 2000; Ferrando, 2009].  
Both, the fact that manipulated expression of transcription factors allows to overcome 
restricted cell fates in trans-differentiation processes, as well as the possibly fatal 
consequences of dys-regulation, underline the power of these factors. This power 
has to be very tightly controlled, which is achieved in a finely tuned network of 
activators and repressors orchestrated by means of epigenetics. 
1.4.3 Epigenetic regulation of hematopoietic differentiation 
As this thesis deals with the epigenetic process of DNA methylation, this chapter will 
focus on the role of this specific process in hematopoietic differentiation. In 2007, 
DNMT3a and DNMT3b were reported to be essential for proper functioning of HSCs. 
Combined loss of both de novo methyltransferases in HSCs drastically impaired their 
self-renewal capacity leading to their inability of long-term reconstitution in trans-
plantation assays. However, Dnmt3a/Dnmt3b deficient HSCs maintained normal 
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differentiation potential as both lymphoid and myeloid progeny were given rise to by 
these cells [Tadokoro, et al., 2007].  
Last year, our group reported a pivotal role for Dnmt1 in HSC fate choices [Broske, et 
al., 2009]. Conditional knockout of the Dnmt1 gene induced apoptosis in HSCs 
causing rapid death of mice as a consequence of complete bone marrow failure. Due 
to this dramatic phenotype further studies applied a knockdown mouse model of 
Dnmt1, combining one Dnmt1 knockout allele (Dnmt1c, further termed as Dnmt1–) 
with a hypomorphic allele. This allele, termed Dnmt1chip (chip = cDNA homologous 
insertion protocol) was created by a Dnmt1 cDNA knockin into the Dnmt1– allele, 
resulting in functional Dnmt1 expression at levels lower than those of the wild type 
[Tucker, et al., 1996]. Dnmt1–/chip mice [Gaudet, et al., 2003] are viable but exhibit 
genomic hypomethylation due to reduced expression levels of Dnmt1. Analysis of the 
hematopoietic system revealed greatly diminished self-renewal capacities of Dnmt1–
/chip HSCs and a severe block in lymphoid differentiation, which was found to be 
caused by the Dnmt1–/chip HSCs’ inability to silence myeloerythroid genes through 
DNA methylation. As summarized in Figure 6, these results showed that distinct 
levels of DNA methylation are required to control different functional programs in 
HSCs, such as self-renewal and alternative lineage choices [Broske, et al., 2009]. 
These observations were supported by a simultaneous report from Stuart Orkin’s lab, 
which stated a similar importance for DNMT1 in HSCs [Trowbridge, et al., 2009]. 
Moreover, a very recent publication offered a comprehensive map of DNA 
methylation in various differentiation stages of the hematopoietic hierarchy, which 
revealed that differentiation towards a lymphoid cell fate involves drastically higher-
level methylation at differentially methylated regions compared to myeloid 
commitment [Ji, et al., 2010]. Although our knowledge about how epigenetic 
processes direct cell fates and which specific molecular interactions contribute to this 
are still in its infancy, DNA methylation is obviously crucially involved in the network 
of orchestration. 





























Figure 6: Model of DNA methylation dosage effects on HSC multipotency 
Alternative HSC fates have different DNA methylation dosage requirements: In a physiological 
situation self-renewal and lymphoid differentiation rely on high methylation levels, whereas lower 
levels suffice to prevent apoptosis and allow myeloid differentiation. Reduced DNA methylation level 
(middle part), resembling the situation in Dnmt1–/chip mice, still allows some essential hematopoiesis 
but greatly diminishes self-renewal capacity and lymphoid pathway choice. If, however, DNMT1 
activity is completely lost (right panel), HSCs undergo apoptosis, excluding any other fate usually 
offered by the HSC’s multipotency. MP, myeloid progeny; LP, lymphoid progeny; †, apoptosis; 
Methyl+++, high methylation level required; Methyl+, low methylation level required. Adapted from 
[Broske, et al., 2009] 
With the role of DNA methylation being that critical for the normal functioning of an 
organism, it stands to reason that any defects in the methylation machinery might 
dramatically interfere with the physiological balance and therefore being a plausible 
cause for disease. 
1.5 DNA methylation and disease 
A growing number of human diseases is known to be caused by or at least 
associated with improperly established or maintained epigenetic information. Among 
them are several diseases categorized as imprinting disorders such as Beckwith-
Widemann syndrome, Prader-Willi syndrome and Angelman syndrome [Robertson, 
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2005]. Mutations in the DNMT3B gene are cause for the majority of ICF 
(Immunodeficiency, centromeric instability and facial anomalies) syndrome cases. 
Hypomethylation due to partial loss of DNMT3B activity leads to instability of 
pericentromeric heterochromatin and disruption of gene expression patterns 
[Hansen, et al., 1999; Xu, et al., 1999]. Mutations in the MECP2 gene coding for one 
of the ‘readers’ of DNA methylation information (see 1.2.2) are cause for the neuro-
developmental disorder Rett syndrome [Amir, et al., 1999]. 
However, most important for this thesis is the fact that almost every cancer displays 
an altered DNA methylation pattern [Yoo and Jones, 2006], a connection which will 
be further introduced in the next chapter.  
1.5.1  DNA methylation and cancer 
A link between DNA methylation and cancer was first demonstrated in 1983, when it 
was shown that cancer cell genomes are hypomethylated relative to their normal 
counterparts [Feinberg and Vogelstein, 1983]. This reduction of methylation marks is 
primarily found in repetitive satellite sequences of the genome such as in 
pericentromeric heterochromatin. CpGs in such regions are usually methylated and 
hypomethylation as found in cancer is associated with genomic instability (Figure 7, 
left) [Robertson, 2005; Yoder, et al., 1997b]. For example several types of cancer, 
like Wilms tumor, breast and ovarian cancer, frequently contain chromosomal 
translocations with breakpoints in the pericentromeric DNA of chromosomes 1 and 
16, which specifically correlate with hypomethylation in the respective regions [Qu, et 
al., 1999]. This suggests that demethylation of satellite sequences might predispose 
to their breakage and recombination [Feinberg and Tycko, 2004]. Furthermore, 
hypomethylation at specific loci might lead to activation of oncogenes. However, 
although known oncogenes like c-myc and H-ras were found to be hypomethylated in 
human tumors, there is no compelling evidence that such local hypomethylation 
causes overexpression of the respective genes to promote tumor development 
[Costello and Plass, 2001]. In fact, DNA hypomethylation in tumors has been 
associated with transcriptional activation of an unexpectedly low number of genes 
[De Smet and Loriot, 2010]. 
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Figure 7: Aberrant DNA methylation in cancer 
This scheme describes the nature of aberrant DNA methylation patterns found in tumor cells. Repeat-
rich heterochromatic regions are frequently hypomethylated, contributing to genomic instability through 
increased mitotic recombination events. Hypermethylated CpG islands in tumor suppressor gene 
(TSG) promoters serves to transcriptionally silence growth-regulatory genes [Robertson, 2005].  
Although most tumors exhibit a global reduction of 5-methylcytosine, the opposite 
phenomenon, DNA hypermethylation, is found at specific loci of tumor cells. Such 
aberrant hypermethylation usually occurs at CpG islands of tumor suppressor gene 
(TSG) promoters, most of which are unmethylated in normal somatic cells. 
Consequently, TSGs become transcriptionally silenced in cancer cells (Figure 7 
right) allowing the cell to discard cell progression antagonists. Aberrant silencing was 
for example shown for the cell cycle regulators p14ARF, p16INK4a and the 
retinoblastoma gene (Rb) [Esteller, et al., 2000b; Merlo, et al., 1995; Simpson, et al., 
2000] as well as for the BRCA1 gene involved in DNA repair [Esteller, et al., 2000a].  
Several tumor-related observations have been made in studies with Dnmt mouse 
models. In 1995, Rudolf Jaenisch’s group showed that hypomethylation, achieved by 
combination of a Dnmt1 heterozygous mouse model with DNMT-inhibitor (5-
azadeoxycytidine) treatment, suppressed the development of intestinal neoplasia in a 
tumor-prone APCMin mouse background [Laird, et al., 1995]. Furthermore, 
overexpression of Dnmt3b in tumor-prone APCMin mice was shown to promote 
tumorigenesis [Linhart, et al., 2007] 
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In contrast to this, other studies suggested a rather pro-oncogenic effect of DNA 
hypomethylation. Tumor-prone mice carrying heterozygous mutations in the tumor-
suppressor genes Nf1 (Neurofibromatosis 1) and p53 were investigated for loss of 
heterozygosity (LOH) in either a Dnmt1 hypomorphic or wildtype context revealing a 
significant increase in LOH rate in a hypomorphic context [Eden, et al., 2003]. In 
addition, some hypomorphic Dnmt1–/chip mice develop T-cell lymphomas later in life 
[Gaudet, et al., 2003]. 
This ambivalent role of DNA methylation in tumorigenesis was most impressively 
demonstrated by Yamada and colleagues who demonstrated opposing effects of 
DNA hypomethylation on intestinal and liver carcinogenesis. Whereas hypo-
methylation promoted the development of early lesions in colon and liver through 
LOH in a Dnmt1–/chip, APCMin mouse model, later stages of intestinal tumorigenesis 
were suppressed in these mice [Yamada, et al., 2005]. 
Taken together, these data suggest a crucial role for DNA methylation in cancer 
initiation and progression, the precise functioning and mechanisms, however, are not 
fully understood yet. Howsoever unclear the role of DNA methylation in 
tumorigenesis is, it should be mentioned that Dnmts themselves are frequently 
overexpressed in tumors. This has, for example, been shown for Dnmt1 in colon 
cancer [Lee, et al., 1996] and leukemia [Melki, et al., 1998] as well as for Dnmt3a and 
3b in cases of acute myeloid leukemia [Mizuno, et al., 2001]. A very recent genome-
wide study of AML patient samples revealed highly recurrent mutations of the 
Dnmt3a gene. Even though these mutations were not accompanied by lower levels 
of 5-methylcytosine and no methylation dependent changes in gene expression were 
observed, patients with mutated Dnmt3a showed significantly reduced overall 
survival. Despite these strong correlations, the mechanism by which these mutations 
act are yet unknown [Ley, et al., 2010]. 
1.5.2 Epigenetic therapy of cancer 
The potential reversibility of DNA methylation marks suggests that they are a viable 
target for a cancer treatment aiming to restore a more normal DNA methylation 
pattern. Treatment of tumor cells with demethylating agents intends to revert hyper-
methylation-induced gene silencing. Targeting of DNMT activity, however, is 
unspecific and cannot be applied for direct demethylation at specific loci. Moreover, 
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demethylating therapy bears the risk of aggravating the situation by further 
demethylating an already hypomethylated genome or activating potentially 
deleterious genes, such as oncogenes [Yoo and Jones, 2006]. Nevertheless, DNA 
methylation inhibitors have been successfully approved for the treatment of specific 
tumor types, primarily hematological malignancies, or are currently tested in clinical 
trials. Most promising results have been obtained with nucleoside-analogue inhibitors 
such as 5-Azacytidine, 5-Aza-2’deoxycytidine (5-Aza-dC; also decitabine) and 
Zebularine [Yoo and Jones, 2006].  
Tumor suppressor gene reactivation was directly shown for patients suffering from 
myelodysplastic syndrome (MDS), who were treated with decitabine. Comparing 
patient samples before and after treatment revealed reversal of hypermethylation of 
the p15 gene, a negative cell cycle regulator, accompanied by its enhanced 
expression [Daskalakis, et al., 2002]. 
As hypermethylation is not the only epigenetic mechanism which silences TSG 
expression, but usually occurs in combination with repressive histone modifications, 
such as histone deacetylation, the effectiveness of demethylating drugs alone might 
be limited. Therefore, a combinatorial treatment with demethylating agents and 
histone deacetylase (HDAC) inhibitors, such as trichostatin A (TSA), might display an 
improved therapeutic option. Combined treatment of a colorectal carcinoma cell line 
with 5-Aza-dC and TSA resulted in synergistic reactivation of hypermethylated TSGs, 
whereas neither agent alone was able to so [Cameron, et al., 1999]. Given this 
synergy of epigenetic therapeutics, combinations of DNMT and HDAC inhibitors are 
currently tested in clinical trials for treatment of acute myeloid leukemia (AML) and 
MDS [Chen, et al., 2010].  
Given the pivotal role of DNA methylation in malignancies, drugs targeting 
methylation aberrations might display a powerful therapeutic approach. If, however, 
the underlying molecular mechanisms were better understood and the target cells 
more clearly identified, the power of such therapeutics could be by far better 
exploited.  
1.5.3  Leukemia stem cells  
The cancer stem cell concept describes a hierarchical model of a tumor cell 
population with a cancer stem cell (CSC) at the apex, analogous to a tissue stem cell 
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at the apex of a given somatic differentiation system. In 1997, the first cancer stem 
cell was identified in human AML as a small subpopulation which was able to transfer 
the disease from the human patient to an immunodeficient mouse [Bonnet and Dick, 
1997]. These cells were designated as leukemia initiating cells or leukemia stem cells 
(LSC). The LSC (as all CSCs) shares functions with its normal, non-malignant 
counterpart, the HSC, such as unlimited self-renewal and the ability to give rise to 
more mature progeny (Figure 8). These abilities are maintained or reacquired by 
epigenetic or genetic aberrations creating a cell with infinite proliferation potential, 
which gives rise to phenotypically diverse progeny [Passegue, et al., 2003]. The 
progeny, also called the leukemic blasts, are usually arrested at a not terminally 














Figure 8: The leukemia stem cell concept 
This simplified scheme depicts the hierarchical organization of both normal hematopoiesis and 
leukemia. Leukemia stem cells (LSCs) are formed by genetic or epigenetic events in HSCs or 
progenitors. LSCs give rise to leukemic blasts which follow a certain lineage pathway but are not able 
to terminally differentiate. 
Concluding, LSCs have to be (re-)equipped with stem cell properties in the process 
of their formation, however, which genetic and epigenetic events underlie this 
transformation remains poorly understood both in case of leukemia as well as for 
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other cancers. 
The existence of CSCs is of great clinical relevance, as their unique stem cell 
properties might enable them to escape conventional cancer therapy which is 
designed to target the rapidly cycling and highly proliferating cancer blasts. This 
inability to eradicate CSCs might be responsible for the disease relapses of cancer 
patients, as the CSC is able to replenish the tumor cell population even after the 
majority of blasts has been eradicated. Consequently, specific anti-CSC therapy is of 
immense clinical importance, however, the restricted knowledge about the molecular 
characteristics of these cells has not allowed the design of such a therapy so far. 
1.6 Aim of this thesis 
Comprehension of the genetic and epigenetic basis of leukemia stem cell (LSC) 
formation is an essential prerequisite for the design of tailored anti-LSC therapy. 
However, the precise mechanisms underlying this process are only insufficiently 
understood. Aberrant patterns of DNA methylation, one of the major epigenetic 
processes, are a hallmark of leukemia, as it is for all cancers. Due to the reversibility 
of epigenetic alterations compared to genetic mutations, therapeutics targeting 
epigenetic processes might be of great potential for such applications. DNA 
methylation was shown to be crucially involved in hematopoietic stem cell (HSC) 
functioning, both in respect to self-renewal as well as differentiation fates. Given the 
similarities of HSCs and LSCs, one might hypothesize that DNA methylation plays a 
comparably important role in LSCs. This thesis aims to investigate how DNA 
methylation is involved in self-renewal and differentiation choices of LSCs and which 
impact it has on the (re-)establishment of stemness in LSC formation. 
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2 Materials and Methods 
2.1 Materials 
2.1.1 General equipment 
7300 Real Time PCR System Applied Biosystems 
Agarose gel chambers Biosteps 
Centrifuge Pico 17 Heraeus 
F96 MicroWell™ Plates Thermo Scientific 
FACS Calibur BD 
FACS LSRII BD 
FACS Fortessa BD 
FACS Aria I BD 
FACS Aria II BD 
FACS Aria III BD 
Geldoc 2000 Biorad 
Hybridization oven Hybridiser HB-1D Techne 
Incubator Steri Cult 200 Forma Scientific 
Incubator Binder 
Laminar Flow Hood BDK 
Luminometer Centro 960 Berthold Technologies 
Mastercycler Gradient Eppendorf 
Microscope DMIL Leica 
Multicentrifuge 3 S-R Heraeus 
Nanodrop Spectrophotometer PeqLab 
Nytran SuperCharge Southern/Northernblot membrane Schleicher&Schuell 
Power supply EV231 Consort 
Stereomicroscope MZ16 with halogen cold light source 
KL1500 LCD 
Leica 
Stratalinker 2400 Stratagene 
SDS gel chambers Biorad 
Thermomixer compact Eppendorf 
Vortex Genie 2 Scientific Industries 
XAR film Kodak 
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2.1.2 Cell culture equipment 
Cell culture dishes, sterile BD 
Cell strainer, sterile, 40, 70 and 100 μm BD 
Centrifuge tubes, sterile, different sizes TPP or Falcon 
Cryotubes, sterile, 1.2 ml Nunc 
Disposable scalpel for single-use, steril Cutfix 
Hemocytometer (Neubauer cell counter chamber) Superior Marienfeld 
MACS® Cell Separation LS Columns Miltenyi 
MACS® MultiStand Miltenyi 
MidiMACSTM Separator Miltenyi 
Needles for single-use, sterile, different sizes Braun 
Polystyrene tubes, 5 ml BD Falcon 
Rotilabo Filter sterile, 0.22 and 0.45 M PVDF Roth 
Serological pipettes Falcon 
Syringes for single-use, sterile, different sizes Braun, Omnifix, BS Plastic 
2.1.3 Mouse dissection equipment 
Dissecting board and pins  
EDTA-treated canula Brand 
Forcipes and scissors of different sizes  
Scalpels, sterile Cutfix 
2.1.4 Chemicals and reagents 




Annexin binding buffer (BD 
-Mercaptoethanol Roth 
Bromphenol blue Roth 
Bovine serum albumin (BSA) Roth 
Chloroform/Isoamylalcohol Roth 
dNTPs Fermentas 
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DTT Roth 
Ethanol absolute  
Ethidium bromide Roth 
Ethylenediaminetetraacetate (EDTA) Roth 
Formaldehyde Roth 
Giemsa Stain Fluka 




High molecular weight marker Fermentas 
Histofix Roth 
Hybri-Quick Roth 
Isoamyl alcohol Roth 
Isopropyl alcohol Roth 
KCl Roth 
KH2PO4 Roth 
LB Agar Roth 
Low molecular weight marker Fermentas 





Phenol Proteinase K (Invitrogen) 
Poly(I:C) GE-Healthcare or Invivogen 
Propidium iodide Sigma Aldrich 
RNase free water Quiagen 
S-Adenosylmethionine (SAM) New England Biolabs 
Sodium dodecyl sulfate (SDS) Roth 
Trichlormethan (Chloroform) Roth 
Tris base Roth 
Tris-Cl Roth 
Trizol: peqGOLD® TriFast PeqLab 
Trypan blue solution Sigma 
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Xylene cyanol Roth 
2.1.5 Buffers and solutions 
6x Loading buffer for agarose gel electrophorasis 0.25 % Bromephenol blue  
0.26 % Xylene cyanol  
30 % Glycerol  
20x SSC 3 M NaCl 
0.3 M sodium citrate 
1 mM EDTA 
ACK red blood cells lysis buffer 0.15 M NH4Cl 
10 mM KHCO3 
0.1 mM EDTA, pH 7.3 
FACS buffer 2 % FCS 
2 mM EDTA  
in PBS 
Freezing medium 10 % DMSO 
in FCS 
Phosphate buffered saline (PBS) 137 mM NaCl,  
2.7 mM KCl,  
10 mM Na2HPO4,  
2 mM KH2PO4 
Southern blot wash solution I 100 ml 20 x SSC 
10 ml 20 % SDS  
890 ml water 
Southern blot wash solution II 10 ml 20 x SSC 
10 ml 20 % SDS in  
980 ml water 
Tail digestion buffer 10 mM Tris-Cl pH 8.0  
10 mM EDTA pH 8.0  
50 mM NaCl  
0.5 % SDS 
TE buffer 10 mM Tris 
1 mM EDTA, pH 7.5 
Tris-acetate-EDTA buffer (TAE) 242 g Tris base 
57.1 ml Glacial acetic acid  
100 ml 0.5 M EDTA, pH 8.0  
in 20l water 
2.1.6 Cell culture media and reagents 
Bovine serum albumin Roth 
Dulbecco’s modified Eagle’s Medium (DMEM), high 
Glucose (4.5 g/l) 
PAA 
Dulbecco’s Phosphate Buffered Saline 1 x, without Ca 
& Mg 
PAA 
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Fetal Calf Serum (FCS) Biochrom 
Fungizone Antimycotic agent Invitrogen 
Gentamicin PAA 
Iscove’s modified DMEM (IMDM) PAA 
MEM Alpha Modification, with L-Glutamine, without 
Ribonucleosides 
PAA 
MethoCult® M3234 Stem Cell Technologies Inc. 
N,N-dimethylsulfoxide (DMSO) Roth 
Penicillin/Streptomycin, 100 x Concentrate Roth 
Polybrene (Hexadimethrine bromide) Sigma-Aldrich 
Retronectin Takara 
RPMI 1640 cell culture medium PAA 
Stable Glutamine, 200 mM Concentrate PAA 
Trypsin EDTA (1:250) 1 x Concentrate PAA 
2.1.7 Enzymes and appending buffers 
Collagenase Sigma 
Proteinase K Invitrogen 
RNase out Fermentas 
DNaseI Fermentas 
10 x Dnase I buffer Fermentas 
EcoR I Fermentas 





10 x Tango buffer Fermentas 
T4 Ligase New England Biolabs 
10 x T4 Ligase buffer New England Biolabs 
Taq polymerase Fermentas 
KCl buffer for PCR Fermentas 
(NH4)2SO4 buffer for PCR Fermentas 
Superscript II Fermentas 
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5 x First round buffer Fermentas 
SssI: CpG Methyltransferase New England Biolabs 
10 x NEBuffer 2 New England Biolabs 
XhoI Fermentas 
10 x Buffer R Fermentas 
2.1.8 Kits 
Calcium Phosphate Transfection Kit for transient 
transfection of PLAT-E cells 
Invitrogen 
Dual-Luciferase® Reporter Assay System Promega 
Invisorb Spin DNA extraction kit for gel extraction Invitek 
Genomic DNA Invisorb Kit III for DNA isolation Invitek 
Rapace Kit for isolation of DNA fragments Invitek 
Rediprime II DNA Labeling System for radioactive 
labeling of DNA 
Amersham 
RNeasy Micro Kit for RNA isolation Qiagen 
RNeasy Mini Kit for RNA isolation Qiagen 
2.1.9 Antibodies 
Target Surface 
Receptor Clone Conjugates Supplier 
B220/CD45R RA3-6B2 PE/Cy5, APC, PE Invitrogen or 
Biolegend 
CD3  145-2C11 PE/Cy5, APC BD Bioscience 
CD4 GK1.5 PE/Cy5 BD Bioscience or  
CD48 HM48-1 APC Biolegend 
CD8  53-6.7 PE/Cy5 Invitrogen or 
Biolegend 
CD11b/ Mac1 M1/70 PE, APC BD Bioscience or 
Biolegend 
CD19 1D3 PE/Cy5, PE Invitrogen or 
Biolegend 
CD34 RAM34 FITC, biotin eBioscience 
CD45 30-F11 PE BD Bioscience 
CD45.1 A40 PE, APC BD Bioscience or 
eBioscience 
CD45.2 104 FITC, APC, biotin BD Bioscience or 
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Target Surface 
Receptor Clone Conjugates Supplier 
eBioscince 
CD48 HM48-1 APC Biolegend 
c-Kit/ CD117 2B8 APC, AlexaFluor780 eBioscience or 
Biolegend 
Fc RII/III 2.4G2 PE BD Bioscience 
Gr1/ Ly6C/G RB6-8C5 PE/Cy5 Biolegend 
Human CD4 (hCD4) MEM-241 PE Abcam 
IgM R6-60.2 APC BD Bioscience 
Sca1/ Ly6A/E E13-161-7 or 
D7 
FITC, PE/Cy7 eBioscience or BD 
Bioscience 
Ter119 TER-119 PE/Cy5 Biolegend 
Annexin-V   BD Bioscience 
Streptavidin  APC/Cy7, PE/Cy7 BD Bioscience  
2.1.10 Micro Beads 
CD117 microbeads Miltenyi 
Compensation Beads Rat IgG,  BD Bioscience 
Dynabeads® Sheep anti-Rat Invitrogen 
2.1.11 Cell lines 
416B [Dexter, et al., 1979] 
E86 [Markowitz, et al., 1988] 
K562 [Lozzio and Lozzio, 1975] 
PLAT-E [Morita, et al., 2000] 
Pu1null [Walsh, et al., 2002] 
2.1.12 Cytokines 
mFlt3L Tebu Bio 
mGM-CSF Tebu Bio 
mIL-3 Tebu Bio 
mIL-6 Tebu Bio 
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mIL-7 Tebu Bio 
mLif R&D Systems 
mSCF Tebu Bio 
mTPO Tebu Bio 
2.1.13 Mouse strains 
Dnmt1–/chip mice [Gaudet, et al., 2003] 
Dnmt1lox/lox mice [Jackson-Grusby, et al., 2001] 
Mx1Cre transgenic mice [Kuhn, et al., 1995] 
B6.SJL-Ptprca wild-type mice Taconic 
129ola wild-type mice breeding in the mouse facility of the Max-
Delbrück-Center, Berlin 
129ola/B6.SJL F1 generation mice breeding in the mouse facility of the Max-
Delbrück-Center, Berlin 
2.1.14 Oligonucleotides and gene expression assays 
Gene/  
Oligo name Application Sequence (5’ – 3’)/ probe ID 
.actin TaqMan® Assay probe, 
endogenous control 
NM_007393.1 
-actin fw Expression PCR AAG GAG ATT ACT GCT CTG GCT CCT A 
-actin rev Expression PCR ACT CAT CGT ACT CCT GCT TGC TGA T 
CHIP242R Genotyping PCR CTG GTA GCC ACG GAA CTA GG 
CHIP48F Genotyping PCR CTT GGA GAA CGG AAC ACA CA 
Csf2r  fw Expression PCR CCA CGG AGG TCA CAA GGT CA 
Csf2r  rev Expression PCR ACT CGC ACG TCG TCG GAC AC 
D beta 2.1 extern TCR rearrangement PCR TAG GCA CCT GTG GGG AAG AAA C 
J beta 2.7 extern TCR rearrangement PCR TGA GAG CTG TCT CCT ACT ATC 
D beta 2.1 intern TCR rearrangement PCR GTA TCA CGA TGT AAC ATT GTG 
J beta 2.7 intern TCR rearrangement PCR GGA AGC GAG AGA TGT GAA TC 
DJ fw1 BCR rearrangement PCR ACG TCG ACT TTT GTS AAG GGA TCT 
ACT ACT GT 
DJ fw2 BCR rearrangement PCR ACG TCG ACG CGG ASS ACC ACA GTG 
CAA CTG 
DJ rev BCR rearrangement PCR GGG TCT AGA CTC TCA GCC GGC TCC 
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Gene/  
Oligo name Application Sequence (5’ – 3’)/ probe ID 
CTC AGG G 
Dnmt1 TaqMan® Assay probe Mm00599783_g1 
Dnmt1 ex32F Genotyping PCR ATC TCG GAA ACG CTG TGG GG 
Dnmt1 ex32R Genotyping PCR CTT ACC TGA GGA AGG AGA CC 
Dnmt1 lox 1 Excision PCR/ Genotyping 
PCR 
GGG CCA GTT GTG TGA CTT GG 
Dnmt1lox_gtyp2 Genotyping PCR CCT GGG CCT GGA TCT TGG GGA 
Dnmt1 lox 2 Excision PCR TGA ACC TCT TCG AGG GAC C 
Dnmt1 lox 3 Excision PCR ATG CAT AGG AAC AGA TGT GTG C 
Ebf1 fw Expression PCR CAA GAC AAG AAC CCT GAA ATG 
Ebf1 rev Expression PCR GTA ACC TCT GGA AGC CGT AGT 
Gapdh-206bp fw Expression PCR AAG GGC TCA TGA CCA CAG TC 
Gapdh-206bp rev Expression PCR CAC ATT GGG GGT AGG AAC AC 
Gata1 TaqMan® Assay probe Mm00484678_m1 




CCC AAG CTT TCC ACT CTG GGT GTC 
ACC TC 




CAT GCC ATG GAT GCA GAG GAT TCA 
GCC ACC 
IRES rev Expression PCR TCC AGA GGA ACT GCT TCC TT 
Koprimer PGK Genotyping PCR GGG AAC TTC CTG ACT AGG GG 
Mpo fw Expression PCR ATG CAG TGG GGA CAG TTT CTG 
Mpo rev Expression PCR GTC GTT GTA GGA TCG GTA CTG 
Mx1Cre fw Genotyping PCR CAA TTT ACT GAC CGT ACA C 
Mx1Cre rev Genotyping PCR TAA TCG CCA TCT TCC AGC AG 
Myc fw Expression PCR CTC TGA AAA GGA CTT ATT GAG GAA AC 
Pax5 fw Expression PCR CGG GTC AGC CAT GGT TGT G 
Pax5 rev Expression PCR GTG CTG TCT CTC AAA CAC G 
Rag1 fw Expression PCR TGC AGA CAT TCT AGC ACT CTG GCC 
Rag1 rev Expression PCR ACA TCT GCC TTC ACG TCG ATC CGG 
Rag2 fw Expression PCR CAC ATC CAC AAG CAG GAA GTA CAC 
Rag2 rev Expression PCR TCC CTC GAC TAT ACA CCA CGT CAA 
Oligonucleotides were provided by Biotez or Metabion. 
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2.1.15 Vectors 
MSCV-IRES-GFP (MIG)  
MSCV-Gata1-IRES-GFP Murine Gata1 cDNA was cloned into MIG via 
XhoI 
MSCV-MLL-AF9-IRES-GFP [Somervaille and Cleary, 2006] 
MSCV-c-Myc-IRES-Bcl2 [Luo, et al., 2005] 
pEYZ-Notch1-IC Retroviral Notch1-IC expression construct 
pCpGL-basic [Klug and Rehli, 2006] 
pCpGL-Gata1 promoter Murine Gata1 promoter cloned into pCpGL 
basic via HindII and NcoI  
pRL-null (Renilla luciferase control 
vector) 
Promega 
Constructs were kindly provided by T. Somervaille (Stanford School of Medicine, 
Palo Alto, CA, USA), M.H. Tomasson (Department of Medicine and Genetics, Saint 
Louis, MO, USA), M. Rehli (University of Regensburg). 
2.1.16 Software 
Software Application Supplier 
7300 System SDS Software Real time RT-PCR analysis Applied Biosystems 
CellQuest Pro Flow cytometry analysis BD 
FACSDiva Flow cytometry analysis BD 
FlowJo Flow cytometry analysis Treestar 
L-Calc Limiting dilution analysis Stem Cell 
Technologies 
TreeView (EisenSoftware) MassARRAY data visualization EisenSoftware 
2.2 Methods 
2.2.1 Molecular biology 
2.2.1.1 Preparation of genomic DNA 
Genomic DNA extraction was performed following standard protocols. In brief, cells 
or tissues were digested with tail digest buffer supplemented with 10 μg/ml 
proteinase K at 56°C over night. Genomic DNA was purified with addition of a 
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phenol/chloroform/Isoamyl alcohol mixture and subsequent centrifugation (13000 
rpm, 5 minutes, 4°C). The upper aqueous phase, which contained the DNA, was 
transferred into a new tube and precipitated with 1 ml pre-cooled ethanol or isopropyl 
alcohol. After centrifugation (13000 g, 20 minutes, 4°C) supernatant was removed 
and the DNA pellet was washed with 1 ml 70 % ethanol. After centrifugation (13000 
g, 5 minutes, 4°C) supernatant was aspired completely and the DNA pellet was air-
dried until ethanol was completely evaporated. DNA was dissolved in H20. 
2.2.1.2 Extraction of RNA 
For RNA extraction of cell-cultured cells or directly FACS-sorted cells, cells were 
resuspended in peqGOLD® TriFast and homogenized through vortexing (for cell 
numbers up to 5 x 105) or through passing through a 16 gauche needle several 
times. After cell lysis, the samples were incubated at RT for 5 minutes to allow the 
dissociation of nucleoprotein complexes. 200 μl of Chloroform were added per ml of 
TriFast reagent, shaken vigorously and incubated for 3 minutes at RT. Phase 
separation was achieved by centrifugation (13000 g, 5 minutes, 4°C), and the upper, 
colorless aqueous phase, which contains the RNA, was transferred to a new tube. To 
precipitate RNA, 500 μl isopropyl alcohol per ml TriFast reagent was added to the 
samples, incubated for 10 minutes on ice and centrifuged (13000 g, 10 minutes, 
4°C). Supernatant was removed and pellet was washed twice with 1 ml 75 % 
ethanol. After the final centrifugation step (13000 g, 10 minutes, 4°C) the supernatant 
was discarded and the pellet was air-dried until ethanol was completely evaporated. 
RNA was re-dissolved in RNase free H2O and incubated (10 minutes, 55°C). In 
general, RNA was stored at -80°C. All buffers, solutions, tips and other equipment 
were RNase free. 
Alternatively, RNA was extracted using RNAeasy Kit according to the manufacturer’s 
instructions. 
2.2.1.3  Reverse transcription of RNA (cDNA synthesis) 
To remove residual amounts of DNA in the RNA preparations, samples were treated 
with DNaseI: 5.2 μl RNA were incubated with 1 μl DNaseI, 0.8 μl 10 x DNaseI buffer 
and 1μl RNase out (15 minutes, RT) followed by inactivation of DNaseI with 1 μl 
                                                                                                2 Materials and Methods 
41 
EDTA (25 μM) and incubation at 65°C for 10 minutes. 2 μl dNTPs (10 mM) and 1 μl 
random hexameres (300 nM) were added to the RNA and incubated for 5 minutes at 
65°C to destroy secondary RNA structures. After a quick chill on ice, 4 μl 5 x first 
strand buffer, 2 μl DTT(mM) and 1 μl RNase out were added and the mixture was 
incubated (10 minutes, 25°C). cDNA synthesis was started with adding 1 μl 
Sperscript II and incubation (42°C, 50 minutes). The synthesis was stopped by 
incubation of the samples at 70°C for 15 minutes. cDNA was stored at -20°C. As a 
control, no RT samples (RNA samples which undergone DNase treatment but no 
reverse transcription) were generated exemplarily and used as a negative control in 
real time RT PCR analysis. 
2.2.1.4 Agarose gel electrophoresis 
Depending on the size of the DNA fragments to be analyzed, gels with an agarose 
content of 0.7-2% (w/v) were boiled in 1xTAE in a microwave. Once dissolved to a 
crystal clear solution, the agarose was cooled down to approximately 50°C. Ethidium 
bromide (0.5μg/ml) was added and poured into casted gel chambers. Gels were run 
in 1xTAE, at 100V. To determine DNA length of the fragments, an appropriate 
standard marker was used. DNA was loaded by addition of appropriate amounts of 
loading buffer and visualized under UV-light. For cloning purposes, DNA fragments of 
interest were excised with a scalpel and extracted using the Invisorb Spin DNA 
extraction kit (Invitek) following manufacturer’s specifications. 
2.2.1.5 Polymerase chain reaction (PCR) and quantitative (real time) RT PCR 
PCR was carried out following standard procedures. All PCR reactions were carried 
out with the following reagents using the indicated final concentrations: 0.25 μM 
forward primer, 0.25 μM reverse primer, 0.5 mM dNTPs, 2 mM MgCl2, 1 x (NH4)2SO4  
or KCl buffer and 5 U/μl Taq polymerase. Either genomic DNA or cDNA was used as 
template. Amplified PCR products were separated and visualized on 1-2 % agarose 
gels containing 1 μg/ml ethidium bromide. For quantitative PCR oligonucleotides 
were designed exon/exon spanning to reduce false positive signals from residual 
DNA contaminations. SYBR green real-time RT-PCR was performed using a 2 x 
SYBR green master mix whereas 2 x Taqman mix and 20 x Taqman assays were 
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used according instructions for TaqMan® Gene Expression Assays. 7300 System 
SDS Software was used to analyze results. 
2.2.1.6 B- and T-cell receptor rearrangement PCR 
D-J rearrangements in the heavy Chain of Ig locus were detected by a PCR strategy 
employing two upstream degenerate primers binding 50 of the DFL/DSP element or 
the DQ52 element. The reverse primer was complementary to a binding site 
downstream of the JH4 segment. All three primers were used in a single PCR 
reaction in a multiplex PCR and the following reaction used in germline configuration, 
the DQ52 and JH4A primers will amplify the 2.15-kb germline fragment. D-JH1, D-
JH2, D-JH3, and D-JH4 rearrangements involving either DFL, DSP, or DQ52 
elements will be detected by the emergence of bands of ~1.46, ~1.15, ~0.73, and 
~0.20 kb, respectively. The amplification protocol was an initial denaturation at 94°C 
for 1 minute followed by 35 cycles of 1 minute at 94°C, 1 minute at 60°C, and 1 
minute 45 seconds at 72°C. Final extension was carried out at 72°C for 10 minutes. 
The status of T-cell receptor (TCR) rearrangement was assessed as described 
previously [Iwasaki-Arai, et al., 2003]. Briefly, a nested PCR was applied to 
investigate the status of the TCR  gene rearrangement. In the first PCR, the 
oligonucleotides J 2.1 ext and J 2.7 ext were used to amplify this part of the TCR  
gene from genomic DNA of FACS sorted myc/bcl2 leukemia cells. After 35 cycles of 
PCR (annealing temperature of 58°C) 20 % of the PCR product were used as 
template DNA for the second PCR, which was performed with the primer pair J 2.1 
int and J 2.7 int. Amplified DNA of the second PCR was electrophoresed on a 1.2 % 
agarose gel.  
2.2.1.7 Retroviral insertion analysis by Southern blot  
To analyze retroviral insertion sites genomic DNA was extracted from different MLL-
AF9 leukemia samples and digested overnight with EcoRI, which cuts once within the 
viral sequence but not within the sequence encoding GFP. Digested DNA was elec-
trophoresed on a 0.7 % agarose gel and subsequently capillary-blotted onto a nylon 
membrane. The blotted DNA was cross-linked to the membrane by UV light using a 
quantitative cross-linker. A 1 kb GFP-specific probe was released from a MIG vector 
                                                                                                2 Materials and Methods 
43 
by cutting the plasmid with NcoI and HindIII and prepared by random-labeling with [ -
32P]dCTP using the Rediprime Labeling Kit. Hybridization of the nylon membrane 
with the P32 labeled GFP probe was carried out for 8-12 h in Roti-Hybri-Quick at 60°C 
and filters were washed twice in 2 x SSC, 0.1 % SDS and twice in 1 x SSC, 1 % SDS 
at 60°C for 15 minutes each. Washed filters were exposed to Kodak XAR film.  
2.2.1.8 In vitro methylation 
A ~800 bp long fragment of the murine Gata1 promoter was amplified by PCR using 
the oligonucleotides ‘Gata1 promoter fw Hind III’ and ‘Gata1 promoter rev NcoI’ and 
cloned into the CpG-free luciferase vector pCpGL-basic [Klug and Rehli, 2006] via 
HindIII and NcoI. In vitro methylation was performed as described in [Klug and Rehli, 
2006]. 30 μg of vector DNA was incubated with SssI (2.5 U/μg DNA) in the presence 
of 160 μM S-Adenosylmethionine (SAM) for four hours at 37°C. Additional 160 μM of 
SAM were added after two hours of incubation. The un-methylated control vector 
DNA was treated the same way but without the addition of SssI. After in vitro 
methylation, the plasmid DNA was purified with phenol/chloroform/isoamyl alcohol 
followed by isopropyl alcohol precipitation. Concentration of the purified DNA was 
assessed using the Nanodrop Spectrophotometer and subsequently used for 
luciferase assays (2.2.1.9). 
Successful in vitro methylation was ensured by processing a CpG site containing 
control plasmid, the MSCV-IRES-GFP, in parallel. This vector was digested either 
with the methylation sensitive restriction endonuclease HpaII or the methylation 
insensitive MspI. The restriction pattern was analyzed by gel-electrophoresis. 
2.2.1.9 Luciferase assay 
K562 cells were transfected with luciferase vectors by electroporation as described 
previously [Nicolis, et al., 1989]: 2 x 107 K562 cells were resuspended in 800 μl of 
PBS and electroporated with 10 μg methylated or un-methylated pCpGL-Gata1 
promoter constructs and 1 μg of Renilla luciferase at 400 V with a capacitance of 400 
μF. After 24 h of culture, the transfected cells were washed with PBS and used for 
luciferase assays, which were performed according to the vendor’s instructions with 
the Dual-Luciferase® Reporter Assay System (Promega) in which the activities of 
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firefly (Photinus pyralis) and Renilla (Renilla reniformis) luciferases are measured 
sequentially from a single sample. Briefly, the cells were lysed in 100 μl 1x Passive 
Lysis Buffer for 15 minutes while shaking and 20μl of lysate were transferred to a F96 
MicroWell™ Plate. After addition of 100 μl Luciferase Assay Reagent II (LAR II), 
firefly luciferase activity was measured, followed by addition of 100 μl Stop & Glo® 
Reagent and measurement of Renilla luciferase activity using a Centro 960LB 
luminometer. For data evaluation, firefly luciferase activity was normalized to the 
internal control luciferase activity (Renilla) to eliminate experimental variances such 
as differences in cell viability, transfection efficiency and cell lysis efficiency. All 
measurements were performed in duplicates. 
2.2.2 Mice 
General mouse work such as daily animal care, breeding and offspring separation 
was carried out in collaboration with the animal core facility of the Max-Delbrück-
Center for Molecular Medicine, Berlin, Germany. All mice were housed and bred in 
specific pathogen-free animal facilities. All animal experiments were approved by the 
local authorities according to the German Federal Animal Protection Act. 
2.2.2.1 Mouse strains 
Wildtype congenic B6.SJL-Ptprca (CD45.1+) mice were purchased from Taconic and 
were crossed with 129ola to obtain 129ola/B6.SJL (CD45.1+/CD45.2+) F1 generation 
animals used as recipients for BM cell transplantation. 129ola mice were used as 
wildtype counterparts for experiments. 
Dnmt1 knockdown mice (Dnmt1–/chip), conditional Dnmt1 knockout mice (Dnmt1lox/lox) 
and transgenic Mx1Cre mice have been described [Gaudet, et al., 2003; Jackson-
Grusby, et al., 2001; Kuhn, et al., 1995]. Dnmt1–/chip mice combine one Dnmt1 null 
allele (deletion of exons 3 and 4) with a hypomorphic Dnmt1 allele. This so called 
“chip” allele (cDNA homologous insertion protocol) was generated by inserting Dnmt1 
cDNA into the locus of the Dnmt1 knockout allele [Tucker, et al., 1996]. A cDNA 
insertion in a knockout locus restores part of the original gene expression but since 
intron and exon structures are lost part of the regulatory network is lost and gene 
expression is reduced. In Dnmt1lox/lox mice, sequences encoding the catalytic domain 
of Dnmt1 (exons 4 and 5) of Dnmt1 are flanked by two loxP sites which are used for 
                                                                                                2 Materials and Methods 
45 
conditional deletion of Dnmt1. In these mice, recombination (excision and 
consequently inactivation of the target gene Dnmt1) occurs only in those cells 
expressing the cyclization recombination protein (Cre recombinase). Cre-mediated 
excision of this flanked region causes an out-of frame splice yielding an mRNA 
encoding the first 67 of 1619 amino acids, thus lacking both the motifs for localization 
and the entire catalytic domain. Transgenic Mx1Cre mice express Cre recombinase 
under control of the IFN-inducible Mx1 promoter which can be activated by 
application of Poly(I:C) [Kuhn, et al., 1995]. These strains were crossed to obtain 
Mx1Cre+Dnmt1lox/chip mice which representing inducible Dnmt1 knockdown mice. 
2.2.2.2 Genotyping 
Mice were genotyped by locus-specific polymerase chain reaction (PCR) on genomic 
DNA extracted from tail tissue (see 2.2.1.5 and 2.2.1.1). 
2.2.2.3 Dissection of mice and preparation of mouse organs 
Mice were euthanized with CO2, rinsed with ethanol and pinned down on a dissecting 
board with the belly facing up. Mice were opened and the upper and lower hind leg 
as well as the front upper leg were dissected with scissors and forceps to isolate BM 
cells. Other organs (spleen, lymph nodes, sternum or thymus) were dissected when 
needed. All organs were kept in cold PBS until preparation. Single cell suspensions 
were generated by cutting the organ into small pieces and subsequently filtering it 
through a cell strainer. BM was isolated by thoroughly flushing the bones with PBS. 
Peripheral blood of living mice was taken from the tail vein with canula treated with 
EDTA to avoid clotting of blood cells. Red blood cells were lysed by incubation the 
cells with 1 ml of ice-cold ACK buffer. Subsequently, cell were washed in PBS. 
Bone marrow stroma cells were isolated by crushing the bones (front and hind legs) 
and subsequent depletion of bone marrow cells by vigorously flushing the bones. 
Bone chips were incubated in serum-free MEM Alpha Modified medium 
supplemented with 0.2% collagenase for 1 hour at 37°C on a rotator. Afterwards, 
stroma cells were separated from residual bone fragments by filtering through a 
100μm cell strainer.  
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2.2.2.4 Transplantation experiments 
For all transplantation assays (except reverse transplantation experiments, see 
below) adult 129ola/B6.SJL (CD45.1+/CD45.2+) F1 generation animals were used as 
recipients (8-12 weeks of age). Prior to transplantation they were irradiated with a 
sub-lethal dose of 6 Gy total body irradiation with the 18-MeV photon beam of a 
linear electron accelerator with a dose rate of 0.18 Gy/min. Donor cells (CD45.2+) in 
desired numbers were resuspended in 200 μl sterile PBS and injected intravenously 
into the tail vein of the fixed animal. 
In case of Myc/Bcl2 transduced LSK cells, 2 x 104 donor cells were injected into 
recipient animals. For Notch1-IC and MLL-AF9 leukemia experiments, 5 x 104 to 1 x 
105 infected cells (YFP+/GFP+) were transplanted into recipients. Mice which had 
received MLL-AF9; MxCre+Dnmt1lox/chip cells were subjected to Poly(I:C) treatment as 
described in 2.2.2.5. Recipient mice were sacrificed when visibly ill and leukemia 
infiltrated organs were investigated by FACS, used for further in vitro studies or 
transplanted into secondary recipients. 
For secondary transplantations and limiting dilution assays the desired number of 
leukemia cells was re-transplanted into secondary recipients. Leukemia stem cell 
(LSC) frequencies were determined using the L-Calc software. Such calculations are 
based on the assumption that LSCs follow a Poisson distribution. The Poisson 
distribution is a discrete probability distribution, which describes the outcome of 
independent experiments according to a yes-or-no answer (two possible outcomes). 
Transferred to the limiting dilution experiment the two possible outcomes are 
leukemia development or no leukemia development.  
For short-term leukemia-cell engraftment assays, 107 leukemia cells were transplan-
ted into sub-lethally irradiated recipient mice. 24 h after transplantation, recipients 
were sacrificed and donor cell contribution in different hematopoietic organs. was 
examined. 
For reverse leukemia-cell transplantations 5000 Dnmt1+/+ MLL-AF9 cells were mixed 
with 1 x 106 Dnmt1+/+ bone marrow cells, which provided support for the recipient 
animals. This cell mixture was transplanted into lethally irradiated (10.5 Gy) Dnmt1–
/chip) or Dnmt1+/+ mice. 
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2.2.2.5 Poly(I:C) treatment 
Mx1Cre mice harbor the Cre recombinase gene under the control of the Mx1 
promoter [Kuhn, et al., 1995]. This promoter is normally silent in mice but can be 
induced to high levels of transcription by administration of interferon alpha, interferon 
beta or synthetic double-stranded RNA (such as Poly(I:C)). When combined with a 
mutant, carrying a gene that is flanked by loxP recognition sites, the expression of 
Cre recombinase causes the excision and removal of flanked genetic region. 
Excision of Dnmt1lox alleles in transplantation-recipients of MLL-AF9 transduced 
Mx1Cre+Dnmt1lox/chip was induced by intraperitoneal injection of 300 μg Poly(I:C) in 
PBS/ mouse every other day for a total of five injections. Mice transplanted with MLL-
AF9 infected Mx1Cre–Dnmt1lox/chip BM cells were used as controls for nonspecific 
Poly(I:C) effects. Excision efficiency was analyzed by PCR. The excised -allele 
generated a 0.25 kilobase (kb) band and the non-excised loxP-flanked allele 
generated a 0.15 kb band. 
2.2.2.6 Histology: May-Grünwald-Giemsa Stain 
2 x 104 to 1 x 105 bone marrow cells isolated from leukemic mice were resuspended 
in 100 μl PBS were attached to a object slide by centrifugation (800 rpm, 5 min,) 
using a cytocentrifuge. Object slides were air-dried and cells were fixed in methanol 
for 5 minutes. For staining procedure, cytospin preparations were stained in May-
Grünwald solution for 5 minutes, rinsed with water and incubate in Giemsa staining 
solution for 45 minutes. Object slides were rinsed in water again, air-dried and 
stained cells were analyzed with a Leica microscope. 
2.2.3 Cell culture 
2.2.3.1 Thawing, general cultivation and freezing of cells 
To be thawed cell lines and primary cells were thawed in a 37°C water bath and 
quickly washed in 10 ml PBS or the respective culture medium to remove DMSO. 
Cells were collected by centrifugation at 1200 rpm for 5 minutes at room temperature 
(RT) followed by removal of the supernatant by Pasteur pipette connected to a pump. 
The cell pellet was resuspended in fresh culture medium and cells were plated in an 
appropriate cell number on culture dishes. 
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For cultivation, cells were cultured in an incubator at 37 °C and 5 % CO2 using the 
respective culture media. Passaging of adherent cells was performed as follows: The 
culture medium was completely removed from the plate, cells were washed with 1 x 
PBS , followed by an approximately 5-minute incubation with 0.05 % trypsin-EDTA at 
37 °C to detach the cells. The detached cells were resuspended in an appropriate 
volume of media and collected by centrifugation (1200 rpm, 5 minutes, RT). The 
desired number of cells was transferred to new culture dishes. Suspension cells were 
collected by centrifugation and re-seeded in the desired density in new cell culture 
flasks or dishes.  
For freezing of cells, they were harvested, resuspended in 1 or 2 ml of ice-cold cryo-
medium (FCS with 10 % DMSO) and transferred into cryo-tubes. Subsequently, cryo-
tubes were chilled to -80°C in styrofoam boxes and, in case of long-term storage, 
transferred to liquid nitrogen. 
2.2.3.2 Assessment of cell number and cell viability 
Harvested cells were collected by centrifugation (1200 rpm, 5 minutes, RT) and the 
cell pellet was resuspended in 1x PBS. To enumerate the cells, 10 μl of the cell 
suspension were mixed with trypan blue solution in dilutions ranging from 1:1 to 1:20. 
and shortly incubated. A small aliquot was transferred to the hemocytometer 
(Neubauer chamber) and checked for equal distribution of the cells in all four big 
quadrants. The cells in at least one large squares were counted and the 
concentration of cells was calculated as follows: cells per ml = cells/square multiplied 
by 10,000. Cells which had taken up the trypan blue solution (blue cells) were 
identified as non-viable cells and excluded during counting. 
2.2.3.3 Cell lines 
Plat-E cells are a retrovirus packaging cell line which was generated based on the 
293T cell line [Morita, et al., 2000]. Plat-E cells were cultured in DMEM, 
supplemented with 10 % FCS and 1 x Penicillin/streptomycin (P/S) and were used for 
the production of retroviral supernatants (see 2.2.3.4). E86 cells [Markowitz, et al., 
1988] are a NIH 3T3 derived murine cell line which produces high levels of the 
retroviral proteins gag-pol and env. They were kept in DMEM, supplemented with 10 
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% FCS and were used for the stable production of high-titer supernatants of the 
MSCV-MLL-AF9-IRES-GFP retrovirus (see 2.2.3.4). K562 cells, a human chronic 
myelogenous cell line [Lozzio and Lozzio, 1975], was kept in RPMI supplemented 
with 10% FCS and 1 x P/S and used for luciferase assays conducted with Gata1-
promoter constructs. 416B cells are a murine myeloid progenitor cell line [Dexter, et 
al., 1979] and were kept in DMEM with 20 % FCS and 1 x P/S. PU1null cells are an 
immortalized cell line established from Pu.1–/– fetal liver cells [Walsh, et al., 2002] and 
were cultivated in DMEM supplemented with 20 % FCS, 1 x P/S and 10 ng/ml IL-3. 
Both 416B cells and PU1null cells were used to test the effects of pharmacological 
demethylation on the expression of myeloerythroid differentiation genes. 
2.2.3.4 Production of viral supernatants and transduction of cells 
Retroviral supernatants were generated by co-transfecting Plat-E cells with 10 μg of 
the respective retroviral construct, 10 μg of a gag-pol construct and 2 μg of an 
ecotropic env construct. Transfection was conducted using the Calcium Phosphate 
Transfection Kit according to instructions. Successful transfections were controlled by 
FACS when GFP-expression constructs were used. Viral supernatants were 
collected at 48, 72 and 96 h after transfection, filtered through 0.45 μm filters and 
stored at -20°C. 
For infections with the MSCV-MLL-AF9-IRES-GFP retrovirus, a stable virus 
producing E86 cell line was generated as follows: Viral supernatant produced as 
described in the preceding passage were used to infect E86 cell. The infection was 
performed with a 1:1 mixture of DMEM medium and viral supernatant, supplemented 
with 8μg/ml polybrene for 48 hours. After infection, the cells were collected and 
infected cells, identifiable by the expression of GFP, were FACS sorted. GFP+ cells 
(further on designated as E86-MLL-AF9-IRES-GFP) were expanded and frozen until 
used for the infection of hematopoietic cells. 
For retroviral transduction of LSK cells or c-Kit enriched cells with the MSCV-c-Myc-
IRES-Bcl2 retroviral construct, cells were pre-stimulated for 24 h at 37°C in medium 
(IMDM, 20 % FCS, 100 μg/ml of penicillin, 2 mM L-glutamine) containing 50 ng/ml 
SCF, 20 ng/ml IL-6 and 20 ng/ml Lif. Subsequently, cells were mixed with retroviral 
supernatants in the presence of 50 ng/ml SCF, 20 ng/ml IL-6, 20 ng/ml LIF and 
8μg/ml polybrene and cultured for 48 h at 37°C.  
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Infections with the MSCV-MLL-AF9-IRES-GFP retrovirus were performed as a 4 co-
culture of E86-MLL-AF9-IRES-GFP and the to be infected bone marrow cells which 
had been pre-stimulated for 24 hours as described in the previous passage. The co-
culture was conducted for 48 h in IMDM, 20 % FCS, 100 μg/ml of penicillin, 2 mM L-
glutamine supplemented with 50 ng/ml SCF, 20 ng/ml IL-6, 20 ng/ml LIF and 8μg/ml 
polybrene. After infection, a small aliquot of cell served to determine the infection rate 
by FACS.  
Infected cells were either transplanted in mice (2.2.2.4) or used for in vitro colony 
assays in methylcellulose (2.2.3.5) . 
Retroviral infections of PU1null cells with MSCV-Gata1-IRES-GFP or MSCV-IRES-
GFP control construct were carried out for 48 h in viral supernatant, supplemented 
with 10 ng/ml IL-3 and 8μg/ml polybrene. Infection rates were determined by FACS. 
2.2.3.5 Serial replating assay in Methylcellulose 
Serial replating assays with MLL-AF9 transformed bone marrow cells was performed 
similarly to previously described [Somervaille and Cleary, 2006]. C-kit enriched bone 
marrow cells were infected with the MSCV-MLL-AF9-IRES-GFP retrovirus or MSC-
IRES-GFP virus as control. Infected cells were FACS sorted and 104 cells were 
plated in methylcellulose medium (M3234, Stem Cell Technologies) supplemented 
with 20 ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6, and 10 ng/ml GM-CSF. 1 ml of this 
suspension was plated onto a 35 mm cell culture dish and three of these dishes were 
put into one 150 mm cell culture dish together with one dish filled with water to 
prevent drying of the semi-solid media. After 5 days, colonies were counted and cells 
harvested from the plates. 5,000 MLL-AF9 transformed cells were re-seeded as 
described before and colony numbers were again scored after 5 days. 4 rounds of 
replating were performed with triplicates for each sample. 
2.2.3.6 5-aza-2'-deoxycytidine treatment 
416B cells, PU1null cells and primary leukemic MLL-AF9 blasts were treated with 5-
aza-2'-deoxycytidine (5-aza) for 72 h. Whereas 416B cells and MLL-AF9 blasts 
received a concentration of 5 μM 5-aza, 1 μM was used for PU1 null cells. Medium of 
control cells was supplemented with the equal volumes of solvent (50 % acetic acid). 
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Medium was exchanged after 48 h and cells were supplied with fresh medium and 5-
aza/solvent. After 72 h cells were harvested and RNA was extracted as described in 
2.2.1.2 or subjected to FACS analysis (only 416B). 
2.2.4 Fluorescence activated cell sorting (FACS) 
2.2.4.1 General flow cytometry and cell sorting. 
Single cell suspensions were immuno-stained with various fluorescence-conjugated 
antibodies listed in chapter 2.1.9. Staining was performed in PBS with the 
fluorochrome-conjugated antibodies usually using a 1:100 dilution for each antibody. 
Samples were incubated in the fridge for 20-40 minutes and subsequently washed 
with PBS to remove excess antibody. In case biotinylated antibodies were used, 
streptavidin fused to a fluorochrome was added in a 1:100 dilution for a secondary 
staining step, followed by a 15-minute incubation in the fridge and subsequent 
washing. Cells were resuspended in FACS buffer and fluorescence intensity was 
measured with a FACSCalibur cytometer equipped with CellQuestPro software or a 
LSRII/Fortessa cytometer and Diva software. Discrimination of dead cells was 
accomplished by staining with propidium iodide (PI) or (DAPI) just before 
measurement. Data analysis was performed with FlowJo software 
For sorting of hematopoietic stem cells (HSCs), here defined as lin–/lowSca-1+c-Kit+ 
[Ikuta and Weissman, 1992; Spangrude, et al., 1988], bone marrow cells were pre-
selected by lineage depletion which was achieved with a lineage “cocktail” of 
antibodies against CD3 , CD4, CD8 , B220, CD19 and Gr-1 (all monoclonal rat 
IgGs). Subsequently, cells positive for these markers were depleted with immuno-
magnetic beads conjugated to polyclonal sheep-anti-rat IgG antibodies. Lineage 
depleted cells (Lin-) were stained with the respective antibodies and cell sorting was 
done with a high-speed multicolor cell sorter (FACSAria) using standard protocols 
For enrichment of stem- and progenitor cells used for infection, either lineage-
negative cells (Lin-) were uused or c-Kit-enrichment was performed with CD117 
microbeads. Before sorting, cells were filtered with a cell strainer. 
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2.2.4.2 Cell cycle analysis 
Propidium iodide (PI) binds to DNA by intercalating between the bases without 
sequence preferences which makes it a suitable dye to quantify the DNA content of a 
cell. This characteristic allows to use PI for the determination of the cell cycle stage 
(G1-S/G2/M-Phase) and also displays a rough method to examine the percentage of 
dead apoptotic cell, which have a DNA content below 2n (Sub-G1). For PI staining 
cells were either directly FACS sorted into 70 % ethanol or cultured cells were 
harvested and added drop wise to pre-cooled ethanol while vortexing. After fixation of 
cells, they were incubated for 15 minutes on ice, followed by the addition of the PI 
solution at a final concentration of 50 μg/ml. Stained cell were measured by means of 
flow cytometry at a maximum emission wavelength of 617 nm. 
2.2.5 MassARRAY 
The quantitative analysis of DNA methylation at single CpG units was performed by 
MassARRAY as previously described [Ehrich, et al., 2005] and schematically 
described in Figure 9. Therefore, 500 ng (sorted primary cells) or 1 μg (cell lines) of 
genomic DNA was treated with sodium bisulfite, PCR-amplified, in vitro transcribed, 
cleaved by RNase A and subjected to matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry. Methylation standards (0, 20, 40, 60, 80 and 100 % 
methylated genomic DNA) and correction algorithms based on the R statistical 
computing environment were used for data normalization. The genomic localization 
of the analyzed regions in the Gata1 and Cd48 locus are the following: Gata1, chr. X 
7545431–7545769 and chr. X 7553755–7554238; Cd48, chr. 1 173612289–
173612577. 
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Figure 9: Concept of the MassARRAY technology 
Genomic DNA undergoes bisulphite treatment and PCR amplified using primers located outside of the 
CpG island with one primer tagged with a T7 promoter sequence. The PCR product is in vitro 
transcribed to RNA, which is then cleaved in a base-specific manner. Analysis of the cleavage 
products is performed with MALDI-TOF mass spectrometry.  
2.2.6 Statistical analysis 
In order to determine the statistical significance of experimental results Student's t-
tests were conducted. *P 0.05 and **P 0.001 
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3 Results 
To address the question how leukemia stem cell function and fate choices are 
affected by DNA methylation, a genetic knockdown mouse model for the main 
somatic methyltransferase DNMT1 was used. This mouse model was chosen, as 
prior observations suggested the assumption that a full knockout of Dnmt1 would 
cause rapid cell death of leukemic cells, consequently not allowing a thorough 
functional analysis of LSCs in the cause of leukemia. First, studies in our lab 
revealed that deletion of Dnmt1 caused a complete failure of the hematopoietic 
system due to rapid cell death of all hematopoietic cells [Broske, et al., 2009]. 
Secondly, complete inactivation of Dnmt1 in human cancer cells led to mitotic 
catastrophe in these cells followed by cell death [Chen, et al., 2007]. Thirdly, 
preliminary in vitro studies were conducted in our lab utilizing retrovirally introduced 
Cre-recombinase into Dnmt1lox/lox conditional Dnmt1 knockout leukemia cells (C. 
Langhans, L. Vockentanz and F. Rosenbauer, unpublished results). These experi-
ments have shown rapid cell death of myeloid leukemia cells upon Dnmt1 deletion 
(data not shown). Based on this knowledge we used the hypomorphic Dnmt1 mouse 
model created in Rudolf Jaenisch’s group [Gaudet, et al., 2003]. These Dnmt1 
knockdown mice are termed Dnmt1–/chip and have been introduced in chapters 1.4.3 
and 2.2.2.1. Reduced Dnmt1 expression has been shown in various Dnmt1–/chip cell 
types, which also included hematopoietic cells. Furthermore, genomic 
hypomethylation has been demonstrated in hematopoietic and other tissues [Broske, 
et al., 2009; Gaudet, et al., 2003]. Dnmt1–/chip mice and an inducible variant of the 
Dnmt1 knockdown mouse model were applied to investigate the role of Dnmt1 in 
leukemogenesis and the results of these studies are presented in the following 
chapters. 
3.1 DNA methylation controls lineage choices of leukemia 
initiating cells 
3.1.1 Myc-Bcl2 induced leukemia in lineage negative cells 
In order to investigate how hypomethylation affects the lineage differentiation choices 
of leukemia initiating cells, I applied a leukemia model, which encompasses both 
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major hematopoietic branches, the lymphoid and the myeloid lineage. A leukemia 
model following these characteristics was known to be achieved by ectopic 
expression of c-Myc and Bcl2. c-Myc is a classical oncogene which acts as a pro-
proliferative transcription factor frequently involved in malignant transformation upon 
its overexpression [Dudley, et al., 2002]. Bcl2 was first isolated in B-cell lymphomas, 
hence the name B-cell lymphoma 2, and it acts as an oncogene by repression of cell 
death [Chao and Korsmeyer, 1998; Vaux, et al., 1988]. Co-expression of these two 
oncogenes was shown to induce a bilinear myeloid/B-lymphoid leukemia in wildtype 
mice [Luo, et al., 2005] thus representing a model encompassing both acute myeloid 
leukemia (AML) and acute (B-)lymphoid leukemia (B-ALL). LSCs in such a bilinear 
disease can be described as bi-potential and have to carry out a lineage decision 
either contributing to the myeloid or the B-lymphoid blast population (Figure 10A). 
Myc-Bcl2 co-expression was achieved by infection of hematopoietic cells with a 
















Figure 10: Myc and Bcl2 co-expression construct induces bilinear leukemia 
A) The co-expression of Myc and Bcl2 creates a bi-potential leukemia initiating cell (LIC) which 
differentiates into either a myeloid or a lymphoid blast. Surface markers describing the two blast 
populations are depicted in the black boxes. B) A murine retroviral MSCV (Murine Stem Cell Virus) 
vector was used for leukemic transformation. Bicistronic Myc-Bcl2 mRNA expression is driven by LTR 
(long terminal repeat) sequences. IRES, internal ribosomal entry site. 
In order to generate a Myc-Bcl2 driven leukemia in an either wildtype or hypo-
methylated background, progenitor enriched bone marrow cells (lin– BM) from either 
Dnmt1–/chip or Dnmt1+/+ mice were infected with a MSCV-Myc-Bcl2 retrovirus. After 
infection, cells were transplanted into sublethally irradiated recipient mice by 
intravenous injection (Figure 11). As hematopoietic cells from donors and recipients 
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carry different variants of the leukocyte common antigen CD45 they can be 
distinguished by FACS analysis, allowing to monitor leukemia development in the 










Figure 11: Experimental setup for Myc-Bcl2 driven leukemia  
Bone marrow cells from CD45.2+ donor mice were isolated and lineage-positive cells were depleted. 
Lineage negative cells (lin–) were infected with Myc-Bcl2 retrovirus and infected cells were 
transplanted into CD45.1+/CD45.2+ SJLx129ola recipient mice, which had previously received a 
sublethal irradiation dose of 6 gray (Gy). BM, bone marrow. 
Both, recipient mice which had received transformed Dnmt1–/chip cells and those 
which had received Dnmt1+/+ cells developed leukemia, characterized by strongly 
elevated white blood cells counts and enlarged spleen and lymph nodes as 
summarized in Table 1. Latency times until mice succumbed to leukemia was 24.0 ± 
2.4 days post-transplantation for recipients of Dnmt1+/+ Myc-Bcl2 cells and 30.7 ± 7.0 
days for recipients of Dnmt1–/chip Myc-Bcl2 cells. Leukemic cells from infiltrated 
organs were analyzed by FACS (Figure 12). This analysis revealed that Dnmt1+/+ 
Myc-Bcl2 leukemias, as expected, consisted of two major blast populations. On the 
one hand, myeloid blast cells, characterized as Mac1+/Gr1+, were present. On the 
other hand an about equally strong lymphoid cell population was found. The 
lymphoid cells were characterized by the B-cell marker B220 and the lack of 
Immunoglobulin M (IgM) on these cells confirmed their immature nature. Contrasting 
to that, this B-lymphoid leukemia cell population was virtually absent in Dnmt1–/chip 
Myc-Bcl2 leuekmias, which almost exclusively consisted of myeloid blasts. These 
findings suggest that hypomethylated LSCs have greatly diminished ability to form a 
B-ALL, however they are still capable of generating an AML. 
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Table 1: Phenotype of Dnmt1+/+ and Dnmt1–/chip Myc-Bcl2 leukemias.  
This table summarizes data from Myc-Bcl2 leukemic animals from experiments shown in chapters 
3.1.1 and 3.1.2 (n=16-17). Parameters collected from non-leukemic wildtype mice are shown for 
comparison. WBC, white blood cell count. 
 
Dnmt1+/+p Myc-Bcl2 Dnmt1-/chip Myc-Bcl2 
Non-leukemic control 
(Dnmt1+/+) 
WBC (103/μl) 178.1 ±137.7 126.5 ± 151.5 12.8 ± 5.6 
Spleen weight (g) 0.68 ± 0.22 0.80 ± 0.34 0.12 ± 0.02 
Lymph node weight 
(mg) 













































Figure 12: Characterization of Myc-Bcl2 induced leukemias by FACS 
FACS analysis of leukemias given rise by transduced Dnmt1–/chip and Dnmt1+/+ cells. Mice were 
autopsied when visibly ill and organs were FACS analyzed in respect to the lineage composition. 
FACS analysis of transplantation donor cells (CD45.2+/CD45.1–) is shown for A) bone marrow and B) 
peripheral blood. The lymphoid blast population is depicted in the upper row of plots characterized as 
B220+ and mostly IgM–. Myeloid blast cells (bottom row) are Gr1+Mac1+. One representative mouse 
from each genotype is shown. Numbers indicate percentages within the respective gates.  
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In order to confirm the transformed nature of Dnmt1 /chip and Dnmt1+/+ Myc-Bcl2 cells 
I transplanted leukemic cells from diseased mice into secondary recipients. As 
depicted in Figure 13 all secondary recipients succumbed to leukemia, demonstra-
ting the malignancy of the transplanted cells. 



























Figure 13: Secondary transplantation of Myc-Bcl2 blasts 
Death curve of secondary recipients re-transplanted with 2x105 leukemia cells isolated from 
Dnmt1 /chip or Dnmt1+/+ Myc-Bcl2 leukemias. In total n = 9 for each genotype (including each 3 
recipients of leukemic splenocytes, thymocytes or lymph node cells.)  
3.1.2 Myc-Bcl2 leukemia from transformed stem cells 
The results presented in the previous section suggested that an actually bi-potential 
leukemia initiating cell is not able to give rise to B-lymphoid blasts in a 
hypomethylated background. However, there is the possibility that the different 
phenotypes of Dnmt1+/+ Myc-Bcl2 and Dnmt1–/chip Myc-Bcl2 leukemias were due to 
differences in the cell population which was used for the initial infection. Our previous 
studies have revealed that Dnmt1–/chip mice lack progenitor cells with generally 
lymphoid or specifically B-cell commitment, such as common lymphoid progenitors 
(CLPs), Pro- and Pre B-cells [Broske, et al., 2009]. Consequently, the Dnmt1–/chip 
cells used for transduction might already have a certain bias for choosing a myeloid 
fate, whereas Dnmt1+/+ cells are susceptible for both lineages. In order to rule out 
such initial transduction biases I repeated this experiment, however, this time 
choosing purified stem cells for the Myc-Bcl2 transduction, representing cells which 
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have not undergone a lineage decision so far. Before performing this experiment, I 
tested whether hypomethylated stem cells are equally infectable and whether they 
expressed the retroviral construct at similar rates. As the MSCV-Myc-Bcl2 construct 
does not feature a fluorescent tag, such as GFP, allowing easy quantification of 
infection rates by FACS analysis, infectability was determined in a parallel infection 
with a non-oncogenic MSCV-IRES-GFP vector. As depicted in Figure 14A both 
Dnmt1–/chip and Dnmt1+/+ stem cells showed very similar infection rates, 
demonstrated by about equal numbers of GFP+ cells. Expression level of the 
retrovirally introduced genes was assessed by real-time RT-PCR, which confirmed 





























































































































Figure 14: Testing stem cell infectability and oncogene expression 
A) Sorted Dnmt1–/chip and Dnmt1+/+ stem cells (LSK) were infected with a MSCV-IRES-GFP retrovirus. 
48 hours after infection, cells were harvested and the proportion of GFP+ (=infected) cells was 
determined by FACS analysis. Percentages of gated cells are indicated. SSC, Sideward Scatter. B) 
Dnmt1–/chip and Dnmt1+/+ LSK cells infected with MSCV-Myc-Bcl2 were harvested 48 hours after 
infection, RNA was isolated and transcription levels were determined by real time PCR after reverse 
transcription. Data were normalized to Gapdh expression. Non-infected cells served as negative 
control. 
To transduce stem cells with the retroviral Myc-Bcl2 construct, LSK cells were sorted 
from bone marrow of Dnmt1–/chip or Dnmt1+/+ mice according to the gating depicted in 
Figure 15A and processed as described in the experimental setup. Leukemia 
development was monitored by blood analysis and moribund mice where sacrificed 
and analyzed. As in the previous experiment, all recipient mice succumbed to 
leukemia, however, mice, which had received Dnmt1–/chip Myc-Bcl2 cells developed 
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leukemia with significantly longer latencies (Figure 15B). Median survival was 27.7 ± 















































Figure 15: FACS sorting of LSK cells and experimental setup 
A) LSK cell were FACS sorted from Dnmt1–/chip or Dnmt1+/+ bone marrow cells as Sca-1+c-Kit+ cells. 
The FACS plot shows cells within lin– gate. After retroviral transduction with Myc-Bcl2 cells were 
intravenously transplanted into sublethally irradiated recipient mice. B) Death curve of Dnmt1–/chip and 
Dnmt1+/+ Myc-Bcl2 leukemic animals induced by transplantation of 104 transduced cells. n=11 
(Dnmt1+/+) and n=8 (Dnmt1–/chip) 
Dnmt1+/+ Myc-Bcl2 leukemias displayed an about equal distribution of myeloblasts 
and lymphoblasts (Figure 16B, upper row). The immature and leukemic nature of 
Dnmt1+/+ Myc-Bcl2 B-cell blasts was again demonstrated by their lack of IgM 
expression in the spleen, compared to residual recipient B-cells in that organ (Figure 
16C). As observed before, Dnmt1–/chip Myc-Bcl2 leukemias were almost completely 
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devoid of lymphoblast and almost exclusively consisted of Mac1+ myeloid leukemia 



























































Figure 16: Hypomethylation in LSCs blocks lymphoid blast development I 
A) Representative FACS plots of bone marrow (BM) and lymph node (LN) suspensions from diseased 
mice demonstrate loss of the neoplastic B cell population in leukemic mice reconstituted with Dnmt1–
/chip Myc-Bcl2 cells. Plots show cells within donor (CD45.2+) gates. B) Immunoglobulin M (IgM) 
expression on Dnmt1+/+ Myc-Bcl2 B cell leukemic blasts (CD45.2+B220+) in recipient spleens. For 
comparison recipient splenic B cells (CD45.1+CD45.2+B220+) are shown. 
As leukemia cells frequently display aberrant cell surface marker expression, it is 
necessary to confirm the absence of B-lymphoid blasts in hypomethylated leukemias 
by other methods than FACS. To this end, Myc-Bcl2 tumor cells were investigated for 
their morphology. Cytospin preparations of leukemic bone marrow cells demon-
strated the presence of both myelo- and lymphoblasts in wildtype leukemias, the 
latter ones, however, were absent in the Dnmt1 /chip leukemias (Figure 17A). 
Furthermore, leukemia cells were analyzed for their expression of genes indicative of 
either myeloid or lymphoid cell identity. Mpo, the gene encoding for myeloperoxidase 
and Csf2r , encoding for the granulocyte-macrophage colony-stimulating factor (GM-
CSF) receptor were chosen as myeloid-specific genes, whereas Pax5 (Paired box 
protein 5) and Ebf1 (Early B cell factor 1) were selected as genes specific for the B-
lymphoid lineage. RT-PCR revealed expression of Mpo and Csf2r  in both 
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leukemias. In contrast, Pax5 and Ebf1 transcripts were exclusively found in Dnmt1+/+ 
























Figure 17: Hypomethylation in LSCs blocks lymphoid blast development II 
A) Cytospin preparations of leukemic bone marrow cells confirming absence of B-cell blasts (red 
arrowheads) and presence of myeloblasts (black arrowheads) in Dnmt1 /chip leukemic mice (May-
Gruenwald stain, ×1,000 magnification). B) Genes indicative of myeloid cells (Mpo, myeloperoxidase; 
Csf2ra, granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor- ) were expressed in 
leukemic bone marrow samples of moribund Dnmt1 /chip Myc-Bcl2 LSK cell–reconstituted mice, 
whereas expression of genes indicative of B cells (Pax5, Ebf1) was not detectable. Shown is one of 
two independent RT-PCR experiments with similar outcomes. Donor-derived blast cell infiltration in 
recipient bone marrow was >95% in all cases.  
3.1.3 Myc-Bcl2 leukemia with aberrant immunophenotype 
As mentioned above, tumor cells frequently show abnormal patterns of cell surface 
marker expression due to non-physiological up- or down-regulation of the respective 
genes. This causes aberrant immunophenotypes which are usually not present on 
normal cells, as for example simultaneous expression of T-lymphoid and myeloid 
markers as well as B-lymphoid and myeloid markers. These kinds of abnormal 
combinations are for instance often found in cases of infant leukemias, which are 
consequently termed mixed lineage leukemia [Rubnitz, et al., 2009]. Aberrant co-
expression of B-lymphoid and myeloid markers was observed in rare cases of both 
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primary and secondary Dnmt1 /chip and Dnmt1+/+ Myc-Bcl2 leukemias (exemplarily 
depicted in Figure 18A for Dnmt1 /chip Myc-Bcl2). Furthermore, I observed co-





















Figure 18: Aberrant immunophenotypes of Myc-Bcl2 leukemias 
A) Dnmt1 /chip bone marrow blasts of simultaneously expressing myeloid (Gr1) and B-lymphoid 
markers (B220). Cells shown are gated on donor cells. B) Dnmt1 /chip bone marrow blast are positive 
for Gr1 (left plot) and also show expression of the T-cell markers CD4 and, in part, CD8 (right plot).  
In order to test whether Gr1+/B220+ leukemia cells rather represent a myeloid blast 
population with aberrant B220 expression or vice versa, the cells were tested for their 
genomic immunoglobulin rearrangement status. B-lineage cells reassemble gene 
segments in the immunoglobulin (Ig) locus to create a great variety of Ig molecules to 
mediate humoral immunity. These alterations are passed on through cell generations 
as they display a change in the genomic sequence. This unique feature allows to 
identify cells, which once belonged to the B-lymphoid lineage, but display 
characteristics (e.g. surface markers) not associated with B-cell identity later on. To 
this end I tested the rearrangement status of Gr1+/B220+ leukemia cells by PCR 
(Figure 19A). In contrast to normal spleen cells which displayed a pattern of different 
rearrangement combinations, Gr1+/B220+ blasts showed germ line configuration of 
the Ig locus indicating that these cells do not originate from the B-cell lineage, but 
merely aberrantly express a B-cell marker. 
Similarly, T-cell lineage origin can be tracked by analysis of the T-cell receptor (TCR) 
gene rearrangement status. Thus, I performed a rearrangement PCR on the TCR  
locus, which revealed that CD4+/Gr1+ cell are derived from the T-cell lineage. These 
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results indicate that while formation of B-cell leukemia is completely abolished by 













































Figure 19: Genomic rearrangement status at immunoglobulin and T-cell receptor loci 
A) PCR on genomic DNA (gDNA) from B220+/Gr1+ blasts sorted from Dnmt1+/+ and Dnmt1 /chip Myc-
Bcl2 leukemias. Spleen cells served as positive control for a rearranged locus; E86 fibroblast cell line 
gDNA served as control for germ line configuration. GL, germ line. Asterisks indicate products of 
different rearrangement combinations B) PCR on gDNA from sorted Dnmt1 /chip CD4+/Gr1+ cells to 
evaluate the rearrangement status of the T-cell receptor  locus. Thymocytes served as positive 
control, bone marrow cells (BM) served as germ line configuration control. GL, germ line.  
Taken together, these results demonstrate that hypomethylation does not allow B-cell 
ALL development from a bi-potential leukemia initiating cell indicating that lineage 
fate choices in leukemia are determined by methylation levels. 
3.1.4 Hypomethylation blocks T-ALL development 
As T-ALL development was observed in rare cases of hypomethylated Myc-Bcl2 
leukemia, I tested whether hypomethylation was generally compatible with growth of 
T-lineage leukemias. Consequently, I chose a specific T-ALL leukemia model 
applying a constitutively active variant of Notch1 as driving oncogene. In normal 
hematopoiesis, Notch1 acts as a key regulator in the commitment of hematopoietic 
progenitors to the T-cell lineage [Aifantis, et al., 2008]. Constitutive Notch1 signaling, 
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achieved by forced expression of the active, intracellular domain of Notch1 (Notch1-
IC) was shown to lead to T cell leukemia formation [Allman, et al., 2001; Pear, et al., 
1996]. I tested whether Notch1-IC induced T-cell lymphomas could be given rise to 
by hypomethylated hematopoietic cells by retrovirally introducing Notch1-IC into 
Dnmt1 /chip progenitor cells. Peripheral blood analysis 18 days post-transplantation 
revealed engraftment of both Dnmt1+/+ and Dnmt1 /chip Notch1-IC cells, however, 
presence of hypomorphic donor cells was markedly lower compared to wildtype 
counterparts. Cells expressing Notch1-IC-YFP were positive for CD3, indicating their 




















































Figure 20: Acute T-cell lymphoma induced by Notch1-IC 
A) FACS analysis of peripheral blood 18 days after transplantation of mice reconstituted with either 
Dnmt1+/+ or Dnmt1 /chip cells transduced with Notch1-IC. Upper plots depict cells within donor gate 
(CD45.1 CD45.2+). Lower plots indicate percentages of Notch1-IC-YFP+ cells. Data from one 
representative animal is shown. B) Survival curve of Dnmt1+/+ or Dnmt1 /chip Notch1-IC reconstituted 
mice. Dnmt1 /chip Notch1-IC recipients did not show Notch1-IC-YFP+ cells 120 days after 
transplantation and were consequently declared disease-free. n=5 for each genotype. C) FACS 
analysis of Dnmt1+/+ leukemias displayed co-expression of CD4 and CD8 on YFP+ cells indicative of T-
ALL.  
Whereas Notch1-IC wildtype control cells were able to induce leukemia in recipient 
mice, transduced hypomethylated cells were not able to initiate leukemia in recipient 
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animals (Figure 20B). Dnmt1+/+ Notch1-IC leukemias displayed an immature T-cell 
phenotype marked by CD4+CD8+ double-positive T-cells (Figure 20C). 
3.2 DNA methylation controls leukemia cell self-renewal 
The studies presented in the previous section revealed that Myc-Bcl2 Dnmt1 /chip 
leukemias developed with prolonged latencies compared to Dnmt1+/+ leukemias. This 
observation suggested that leukemia stem cells (LSCs) rely on constitutive DNA 
methylation to perform proper self-renewal. However, Myc-Bcl2 Dnmt1 /chip leukemias 
are devoid of the neoplastic B-cell population, which might also be causal for delayed 
leukemia onset. Consequently, in order to test the dependency of LSC self-renewal 
on constitutive DNA methylation, a leukemia model with a uniform, homogenously 
myeloid phenotype would be preferential. For this reason I chose the MLL-AF9 fusion 
as oncogene, which induces an acute myeloid leukemia (AML) in mice [Corral, et al., 
1996]. MLL-AF9 is one of more than 60 fusion products of chromosomal 
translocations involving the human mixed lineage leukemia (MLL) gene, which are 
predominantly found in infant leukemia and occur in patients with AML and ALL as 
well as in a substantial proportion of biphenotypic mixed-lineage leukemias, 
[Dimartino and Cleary, 1999; Meyer, et al., 2009]. MLL fusion proteins display potent 
transcriptional activators. In MLL-mediated leukemogenesis MLL-target genes, which 
mostly belong to the transcription factor group of Hox (homeobox) genes, are 
constitutively activated inhibiting hematopoietic maturation and leading to leukemia 
[Slany, 2005].  
3.2.1 Reduced self-renewal of hypomethylated leukemia cells in vitro 
MLL-AF9 has frequently been used as an oncogene in leukemia research and it can 
be applied for transforming hematopoietic cells in vitro, providing cultured cells with 
unlimited proliferation capacities. Moreover, MLL-AF9 can be used to induce AML in 
mice upon transplantation of transduced cells [Somervaille and Cleary, 2006]. In 
order to investigate the effect of DNA hypomethylation on leukemic self-renewal, I 
conducted an in vitro serial replating assay in semisolid methylcellulose. Cells 
growing in such semisolid medium form colonies originating from a single starting cell 
and in case of MLL-AF9 transformed cells, it has been shown that cells expanded 
                                                                                                                         3 Results 
67 
from every colony have the capacity to induce a leukemia in mice upon their 
transplantation [Somervaille and Cleary, 2006]. Hence, colony assays display a 
valuable tool to quantify self-renewal capacities by counting the number of colonies 
growing from a certain number of cells. In serial replating assays a specific cell 
number is seeded in methylcellulose and after several days of culture colony 
numbers are determined and a certain number of cells is re-seeded on the next plate. 
This can be applied for several rounds of replating given that there is colony growth 
during the previous round. Hematopoietic cells without transforming event posses 
very limited self-renewal capacities, which is rapidly ‘out-diluted’ during in vitro culture 
leading to decreasing colony formation in the course of replating rounds. On the 
contrary, if cells are transformed with an oncogene such as MLL-AF9, they acquire 
unlimited self-renewal causing increasing colony formation and allowing virtually 
infinite replating. Thus, Dnmt1 /chip and Dnmt1+/+ cells were immortalized with a 
retroviral MLL-AF9 fusion construct and a serial replating experiment was performed 
(Figure 21A). To test whether Dnmt1 /chip cells generally show the same response to 
growth factors in the culture medium as Dnmt1+/+ cells, leading to equal colony 
numbers under non-transforming conditions, I assessed colony numbers of cells 
infected with a MSCV-IRES-GFP construct. As depicted in Figure 21B both 
Dnmt1 /chip GFP+ and Dnmt1+/+ GFP+ cells gave rise to equal numbers of colonies 
suggesting that the overall colony-forming ability is not affected by DNA 
hypomethylation. In contrast to that, Dnmt1 /chip cells transduced with MLL-AF9 
showed a severe replating deficiency compared to their wildtype counterparts, 
indicating that they had impaired self-renewal capacity in vitro (Figure 21C).  





































































Figure 21: Assessment of leukemic self-renewal by colony assays 
A) Experimental setup for in vitro colony assay of MLL-AF9 transformed Dnmt1+/+ and Dnmt1 /chip bone 
marrow cells B) Dnmt1+/+ and Dnmt1 /chip bone marrow cells transduced with GFP-expressing control 
virus gave rise to equal numbers of colonies in methylcellulose. Experiment was done in triplicates; 
data show is mean ± s.d. C) Serial replating assay of MLL-AF9–transduced Dnmt1+/+ and Dnmt1 /chip 
bone marrow cells. GFP+ cells were sorted, and for each round, 5,000 cells were plated in 
methylcellulose. After 5 d, colonies were counted and cells were re-seeded on the next plate. Data 
show mean ± s.d of one representative experiment. Experiment was done twice in triplicates.  
3.2.2 Reduced self-renewal of hypomethylated leukemia cells in vivo 
Having demonstrated that leukemic self-renewal is diminished due to hypo-
methylation in vitro, I investigated self-renewal potential of hypomethylated MLL-AF9 
leukemias in vivo. For this experiment an inducible Dnmt1 knockdown mouse model 
termed Dnmt1lox/chip was applied (description see 2.2.2.1). Crossing these mice with 
Mx1Cre mice allows to induce Cre-expression and consequently Dnmt1 knockdown 
by injection of Poly(I:C). The ‘floxed’ allele is termed Dnmt1lox, whereas the functional 
knockout allele which is created by Cre-excision is termed Dnmt1 . This conditional 
Dnmt1 knockdown mouse model was chosen to avoid any experimental bias due to 
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unequal engraftment capacities of hypomethylated cells, as the Dnmt1lox allele is 
excised after transplantation and engraftment of cells (Figure 22A). To control the 
results obtained with Dnmt1lox/chip MxCre cells they were compared to Dnmt1lox/chip 
cells without the MxCre allele. Recipient mice of MLL-AF9 transduced cells were 
injected with Poly(I:C) three weeks after transplantation to trigger Dnmt1 excision in 
those cells carrying the MxCre allele and leukemia development was monitored by 





















Figure 22: MLL-AF9 leukemia with conditional Dnmt1 knockdown cells 
A) Experimental setup: Lin  BM cells from Dnmt1lox/chip MxCre or Dnmt1lox/chip mice were infected with 
MLL-AF9 retrovirus and transplanted into sublethally irradiated SJLx129ola recipients. Three weeks 
after transplantation, recipients were injected with Poly(I:C) every other day for a total of five injections. 
B) PCR on genomic DNA from Dnmt1 /chip MLL-AF9 and Dnmt1lox/chip MLL-AF9 leukemia cells 
confirms near-complete excision of the Dnmt1lox allele. 
Similar to the Myc-Bcl2 model, Dnmt1 /chip MLL-AF9 cell transplantation led to 
leukemia with prolonged latency with a median survival after Poly(I:C) of 48.2 ± 11.8 
days (Dnmt1lox/chip MLL-AF9) and 61.95 ± 13.5 days (Dnmt1 /chip MLL-AF9), re-
spectively (P = 0.0005). The cells of Dnmt1 /chip MLL-AF9 leukemias displayed near-
complete excision of the Dnmt1lox allele (Figure 22B). 
Furthermore the leukemias were characterized concerning their clonality, the cells’ 
surface marker phenotype and the histological status of the infiltrated organs (Figure 
23A-C). Leukemic cells found in bone marrow, spleen, thymus, blood and lymph 
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nodes were all positive for the myeloid marker Mac1. The majority of blast cells co-
expressed the ‘progenitor marker’ c-Kit, a marker which is usually, i.e. in a 







































Figure 23: Characterization of MLL-AF9 leukemias  
A) Representative FACS plots of GFP+ splenocytes of Dnmt1lox/chip MLL-AF9 and Dnmt1 /chip MLL-AF9 
diseased animals. B). Southern blot analysis of genomic DNA isolated from spleens of each four 
lox/chip and /chip MLL-AF9 leukemic mice using a GFP-specific probe showed a comparable 
number of retroviral integration sites. C) Histological analysis of infiltrated spleens with hematoxylin 
and eosin staining. The right pictures show the magnification of the area indicated by the white box in 
the left pictures, respectively. Sizes are indicated by the measure in the pictures. Histological analyses 
were performed by Marco Prinz (University of Freiburg). 
To analyze the clonality status of the leukemias, genomic DNA from leukemic cells 
was digested with two different enzymes, with one of them cutting within the inserted 
retroviral sequence and the other one not cutting within this area. Subsequent 
southern blotting and hybridization with a GFP-specific probe demonstrated that both 
lox/chip and /chip leukemias were oligoclonal with comparable numbers of 
integration sites (Figure 23B). Histological analysis of leukemic spleens, which was 
done in cooperation with Marco Prinz (University of Freiburg) showed high infiltration 
of leukemia cells causing damage and disappearance of physiological lymph follicle 
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structures (Figure 23C).  
These data indicate an impaired development of Dnmt1 /chip leukemias causing 
prolongation of disease latency. The phenotype of the emerging leukemias, however, 
is the same. 
3.2.3 Hypomethylation causes reduction of functional LSCs 
The results presented in the previous section suggested decreased self-renewal 
abilities of hypomethylated leukemia cells, however, the impairment of cells with self-
renewal potential, the LSCs, was not quantified. To this end, I performed a limiting 
dilution experiment, which allows to determine the number of cells possessing LSC 
function within a given leukemia. This experiment is based on the fact that LSCs are, 
depending on the type of leukemia, not precisely or not at all phenotypically 
characterized and thus not identifiable. However, LSCs are defined by their function, 
which is that they are able to initiate a leukemia from a single cell level. According to 
this definition, the transplantation of a single LSC should be able to give rise to 
leukemia in the recipient. In a limiting dilution experiment, decreasing numbers of 
leukemia cells are transplanted into recipient mice and the proportion of recipients 
developing leukemia allows to determine the number of functional LSCs in the donor 
population. The experimental setup is illustrated in Figure 24A and the results from 
the experiment are summarized in Table 2. The obtained results allow to calculate 
the frequency of functional LSCs within the leukemic cell population: An LSC 
frequency of 1 in 91 Dnmt1lox/chip MLL-AF9 cells and 1 in 1,072 Dnmt1 /chip MLL-AF9 
cells was determined for the respective leukemias. Additionally to this clearly reduced 
LSC frequency, diminished stem cell function is also visible from the drastic latency 
differences in the low cell number transplantations (Figure 24B). 












































Figure 24: Limiting dilution experiment 
A) Experimental setup of limiting dilution assay: 10,000, 1,000 or 100 Dnmt1lox/chip MLL-AF9 and 
Dnmt1 /chip MLL-AF9 leukemic cells were transplanted into sublethally irradiated secondary recipients. 
B). Survival of secondary recipient mice injected with limiting dilutions of lox/chip or /chip MLL-AF9 
bone marrow cells (containing >95% GFP+ leukemic cells).  
Table 2: Occurrence of leukemia in recipients transplanted with MLL-AF9 leukemia cells in 
limiting dilution experiment 

















10,000 6 6 26 6 6 69 
1,000 6 6 35 6 4 98 
100 6 4 98 6 0 - 
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Given the huge discrepancy in the aggressiveness of Dnmt1 /chip leukemias 
compared to Dnmt1lox/chip leukemias, it was further investigated whether this is 
exclusively based on reduced functioning of LSCs or whether the whole leukemia 
bulk is affected by hypomethylation. To assess this, /chip leukemic blasts as well as 
the control cells were cultured in vitro. After several passages, cell cycle profiles of 
harvested cells were determined by propidium iodide FACS analysis. This revealed 
























Figure 25: Proliferation of MLL-AF9 leukemia bulk cells 
Dnmt1lox/chip and Dnmt1 /chip MLL-AF9 blasts were cultivated in vitro for three weeks in liquid culture 
with growth conditions for myeloid cells (IL3, IL6 and SCF). Harvested cells were ethanol-fixed, 
stained with propidium iodide and analyzed by FACS. Apoptotic cells and doublets were gated out. 
3.2.4 Leukemogenesis is unaffected by hypomethylated stroma 
The results presented in the previous chapters revealed that hypomethylation of 
leukemic cells strongly affects their function both concerning their lineage 
differentiation potential and their stem cell self-renewal. These effects were clearly 
cell intrinsic as in the chosen experimental setup hypomethylated leukemias were 
generated in wildtype recipient mice. Consequently, any effects due to 
hypomethylation result from the transplanted leukemia cells, with stroma cells of the 
recipient mouse being normally methylated. In order to test whether the methylation 
status of the recipients’ bone marrow niche is critical for leukemia development, I 
generated wildtype (Dnmt1+/+) MLL-AF9 induced leukemic mice. Cells isolated from 
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these mice were subsequently transplanted into recipients providing either hypo-
methylated (Dnmt1 /chip) or normally methylated (Dnmt1+/+) bone marrow microen-
vironment. To avoid any experimental bias from cell-to-cell interactions between 
leukemia cells and differentially methylated recipient cells, recipient bone marrow 
cells were removed by lethal irradiation. Recipients received Dnmt1+/+ bone marrow 
support alongside the leukemic cells creating a leukemia model with Dnmt1+/+ 
leukemia and hematopoietic system in a hypomethylated niche. Figure 26A 
illustrates that leukemias developed with similar latencies in Dnmt1+/+ and Dnmt1 /chip 
recipients. Dnmt1+/+ recipients succumbed to leukemia with a median latency of 50.5 
± 15.0 days and Dnmt1 /chip recipients developed leukemia after 56.4 ± 17.1 days (P 
= 0.60).  














































































Figure 26: Leukemia development in hypomethylated microenvironment 
A) 5000 Dnmt1+/+ MLL-AF9 leukemia cells were transplanted into lethally irradiated (10.5 Gy) 
Dnmt1 /chip or Dnmt1+/+ recipients. 106 Dnmt1+/+ bone marrow cells were transplanted as support 
alongside to provide radioprotection. Survival curve depicts leukemia development of 4 (Dnmt1+/+) or 5 
(Dnmt1 /chip) recipients respectively. B) Real time RT-PCR of Dnmt1+/+ and Dnmt1 /chip bone marrow 
stroma cells confirmed down-regulation of Dnmt1 expression. Data were normalized to the expression 
of -actin. Results represent the mean ± s.d. of two independent experiments. 
Furthermore, the leukemia phenotype was not influenced by the genotype of the 
recipient (data not shown). Dnmt1 knockdown in Dnmt1 /chip stroma cells was 
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successfully confirmed as shown in Figure 26B. These data suggest that, in contrast 
to the striking cell intrinsic effects of hypomethylation on leukemia development, the 
methylation status of the bone marrow stroma does not affect leukemic growth or 
phenotype. 
3.3 Hypomethylated LSCs display impaired self-renewal 
The data presented in chapter 3.2 suggested that hypomethylation strongly interferes 
with LSC function. However, in all experiments stem cell function was tested in the 
context of the bulk leukemia. In case of MLL-AF9 driven leukemia in mice, several 
studies have been dedicated to phenotypically describe the LSC. Scott Armstrong’s 
group found a highly enriched incidence of LSCs in a subpopulation of MLL-AF9 
leukemia cells, which featured a cell surface marker composition (IL-7R Lin Sca-1 c-
KithighCD34+Fc RII/III+) usually found on granulocyte-monocyte progenitors (GMPs). 
The accordingly termed GMP-like leukemic cells (L-GMP) were found to contain 
leukemia-initiating cells with a frequency of approximately 1 in 6 cells [Krivtsov, et al., 
2006]. Further studies found LSC activity to be enriched in the Lin c-Kit+ 
compartment of MLL-AF9 leukemia cells [Somervaille and Cleary, 2006; Somervaille, 
et al., 2009]. In conclusion of these two findings, c-Kit appears to be one of the most 
critical markers defining cells with LSC function in MLL-AF9 driven leukemias.  
3.3.1 Generation of Dnmt1 /chip MLL-AF9 leukemias 
In order to more thoroughly investigate effects of hypomethylation on LSC function, I 
purified cells highly expressing c-Kit to test their self-renewal abilities both in vitro and 
in vivo. The inducible Dnmt1-knockdown model applied in the previously described 
experiments turned out to be sub-optimal for studies involving repeated rounds of 
transplantation, as, over time, cells which had escaped Dnmt1-excision and conse-
quently displayed a growth advantage due to a wildtype-like methylation status, 
overgrew the excised, hypomethylated cells (data not shown). For this reason I gen-
erated leukemias originating from MLL-AF9 transduced Dnmt1 /chip bone marrow 
progenitors or their wildtype counterparts (Dnmt1+/+), respectively. To this end 
Dnmt1 /chip and Dnmt1+/+ cells were retrovirally transduced with MLL-AF9 and 
transplanted into recipient animals. All but two Dnmt1 /chip MLL-AF9 recipients 
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developed AML, however, mice which developed leukemia displayed significantly 
increased disease latencies of 140.8 ± 37.0 days compared to the wildtype 
counterparts, which succumbed to AML after a median latency of 89.8 ± 24.1 days 






























Figure 27: Dnmt1 /chip and Dnmt1+/+ MLL-AF9 leukemia development 
Survival curve depicts leukemia development of 9 (Dnmt1+/+ MLL-AF9) or 12 (Dnmt1 /chip MLL-AF9) 
recipients respectively. Two recipients of Dnmt1 /chip MLL-AF9 were devoid of GFP+ cells after 250 
days post-transplantation and were consequently considered as disease-free. 
To exclude engraftment deficiencies of Dnmt1 /chip MLL-AF9 cells to be responsible 
for prolonged disease latencies, I performed a short-term engraftment assay, in 
which Dnmt1 /chip and Dnmt1+/+ leukemia cells were tested for their ‘homing’ capacity 
to the recipients’ hematopoietic organs following intravenous injection. Analysis of 
bone marrow and spleen of recipient animals 20 hours after transplantation revealed 
an equal contribution of Dnmt1 /chip and Dnmt1+/+ leukemic cells in these organs and 
consequently comparable engraftment abilities (Figure 28). 

































































Figure 28: MLL-AF9 leukemic blast homing 
107 Dnmt1 /chip or Dnmt1+/+ unsorted leukemia cells were transplanted into sublethally irradiated 
SJLx129ola mice. Recipients were sacrificed 20 hours post-transplantation. Each square box in the 
plot represents the mean percentage of GFP+ donor cells in bone marrow (left) and spleen (right) of 
three recipients injected with leukemic cells from one donor. 4 Dnmt1+/+ MLL-AF9 and 5 Dnmt1 /chip 
MLL-AF9 leukemias were analyzed for their short-term engraftment ability. The black bars indicate the 
mean percentage of GFP+ cells of all 4 or 5 transplantations, respectively. Both bone marrow (P = 
0.52) and spleen (P = 0.55) displayed no statistically significant differences in short-term homing 
capacity. 
3.3.2 Hypomethylated LSCs display impaired self-renewal 
Having successfully generated Dnmt1 /chip and Dnmt1+/+ MLL-AF9 leukemias, a cell 
population enriched for LSCs was purified from the leukemia bulk. To this end the c-
Kit highest expressing leukemic cells, further on termed as c-Kithigh, were FACS-
sorted as illustrated in Figure 29A.  
To ensure that Dnmt1 /chip MLL-AF9 LSCs are harbored within the c-Kithigh compart-
ment, the c-Kit lowest expressing leukemia cells (c-Kitlow) were sorted for 
comparison. Both c-Kithigh and c-Kitlow cells were plated in methylcellulose and colony 
numbers scored after 5 days of culture revealed consistently more colonies growing 
from c-Kithigh cells. Cultured c-Kithigh cells yielded 7.5 (Dnmt1+/+) or 5.5 (Dnmt1 /chip) 
times more colonies than c-Kitlow cells of the respective genotype. These data 
confirmed that LSCs are enriched in the c-Kithigh cell population both in 
hypomethylated as well as in normally methylated leukemias (Figure 29B). 































































































Figure 29: Purification and testing of MLL-AF9 LSCs 
A) Scheme for FACS sort purification of Dnmt1+/+ and Dnmt1 /chip MLL-AF9 LSC enriched population. 
c-Kithigh cells were sorted as the 10% c-Kit highest expressing cells and for comparison the 10% c-Kit 
lowest expressing cells were sorted (c-Kitlow). FACS plots are gated on GFP+ donor cells. Red boxes 
indicate the sorting gates. Purified populations are depicted in the right respective plots. B) 500 Sorted 
Dnmt1+/+ and Dnmt1 /chip c-Kithigh and c-Kitlow cells were plated in methylcellulose in the presence of 
IL3, IL6 and SCF and colonies were scored after 5 days. Values are mean ± s.d. number of colonies 
from 4 leukemias per genotype. 
Furthermore, I tested Dnmt1 expression in sorted c-Kithigh cells to ensure that 
hypomethylation also occurs in this specific cell population. For this purpose, c-Kithigh 
cells from several individual leukemias were individually tested for Dnmt1 expression 
by real-time RT-PCR, the results of which are depicted in Figure 31. Dnmt1 was 
found to be consistently down regulated in all tested Dnmt1 /chip samples. On 
average, Dnmt1 expression was reduced to 35.4% of wildtype Dnmt1 level. Similarly, 
Dnmt1 expression was decreased in Dnmt1 /chip c-Kitlow cells, which displayed 41.1% 
expression of wildtype Dnmt1 (data not shown). 



































Figure 30: Reduced Dnmt1 expression in Dnmt1 /chip MLL-AF9 LSCs 
Dnmt1 real-time RT-PCR on FACS sort purified Dnmt1+/+ and Dnmt1 /chip MLL-AF9 c-Kithigh cells. 
Cells from 6 or 8 individual leukemias were tested, respectively. Values are mean ± s.d. of technical 
replicates. 
To investigate self-renewal potential of LSC enriched leukemia cell populations, c-
Kithigh cells were sorted from Dnmt1+/+ and Dnmt1 /chip MLL-AF9 leukemias, cultured in 
methylcellulose and subsequently replated as described before. Dnmt1+/+ MLL-AF9 
colony numbers slightly decreased in the second round but in the subsequent rounds 
Dnmt1+/+ LSCs stably replated with constant colony numbers (Figure 31A). In 
contrast, Dnmt1 /chip LSCs yielded continuously decreasing colony numbers over four 
replating rounds (Figure 31B). These data suggest a progressive loss of self-renewal 
capacity in Dnmt1 /chip c-Kithigh populations, whereas leukemic self-renewal is 
maintained in case of wildtype LSCs.  


































Figure 31: Serial replating of MLL-AF9 LSCs 
Bone marrow cells were isolated from leukemic Dnmt1+/+ and Dnmt1 /chip MLL-AF9 mice. 500 FACS 
sorted c-Kithigh cells were plated in methylcellulose and replated after 5 days for a total of 4 rounds. 
Graphs illustrate colony numbers of Dnmt1+/+ and Dnmt1 /chip MLL-AF9 LSC replating assays. For each 
genotype c-Kithigh cells from 4 individual leukemic animals were used. Values are mean ± s.d.. 
To confirm the results gathered in the in vitro replating assays in an in vivo approach 
a limiting dilution assay with purified LSCs (c-Kithigh cells) was conducted as 
described in section 3.2.2. The results of this limiting dilution experiment are 
summarized in Table 3 and survival curves of recipient mice are depicted in Figure 
32. Based on these numbers an LSC frequency of 1 in 33 was calculated for 
Dnmt1+/+ MLL-AF9 c-Kithigh cells. In Dnmt1 /chip MLL-AF9 c-Kithigh cells, however, the 
determined LSC frequency was 1 in 478, consequently representing an 14.5 fold 
decreased frequency of functional LSCs. As observed in all previously described 
transplantations, development of hypomethylated leukemias took place with 
drastically prolonged latencies, presenting further prove for diminished leukemic 
potential of hypomethylated LSCs. 
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Figure 32: Limiting dilution experiment with sorted c-Kithigh leukemia cells 
Sublethally irradiated recipient mice were transplanted with 20,000 (only Dnmt1-/chip, not depicted 
here), 5,000, 500, 100, 50 or 10 Dnmt1+/+ or Dnmt1-/chip FACS sorted c-Kithigh MLL-AF9 leukemic cells. 
Survival curves of recipient mice of 5,000 and 500 cells (A) and 100, 50 and 10 cells (B) are depicted. 
Mice which did not display GFP+ cells after 200 days were considered as disease-free. 
                                                                                                                         3 Results 
82 
Table 3: Occurrence of leukemia in recipients transplanted with FACS sorted c-Kithigh MLL-
AF9 leukemia cells in limiting dilution experiment 

















20,000 - - - 4 4 37.8 
5,000 6 6 28.2 9 9 50.7 
500 9 9 35.2 12 8 63.0 
100 9 8 45.4 12 3 96.7 
50 9 7 76.4 10 0 - 
10 9 4 92.0 6 0 - 
 
3.4 Hypomethylation induces expression of differentiation 
genes 
3.4.1 Pharmacological demethylation activates differentiation factors 
In our previous studies of hypomethylation effects on hematopoietic stem cell (HSC) 
fates, we found that impaired HSC function in Dnmt1 /chip mice is caused by 
premature expression of differentiation factors in these cells. In microarray based 
gene expression analysis, we found that transcriptomes of Dnmt1 /chip HSCs were 
more closely related to myeloid progenitors compared to their wildtype counterparts. 
Several myeloerythroid specific factors were found to be increasingly expressed in 
the Dnmt1 /chip HSC leading to partial differentiation of these cells causing diminished 
stem cell activity [Broske, et al., 2009]. Based on these findings activation of 
myeloerythroid genes caused by demethylation might display a mechanism by which 
hypomethylation can generally inhibit the renewal of cancer cells. To test this 
hypothesis, I treated different murine myeloid leukemia lines and primary myeloid 
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leukemia cells with 5-aza-2 -deoxycytidine (5-Aza-dC). After treatment, expression of 
Gata1 and Cebp  on mRNA level and expression of the cell surface marker CD48 
was measured by FACS analysis. Whereas Cebp  expression remained unchanged, 























































































Figure 33: Activation of differentiation factors after demethylation I 
A) Real time RT-PCR of Cebp  and Gata1 in two myeloid cell lines, 416B and PU1null, and primary 
leukemia cells derived from a moribund MLL-AF9 Dnmt1+/+ mouse after 72 hours of treatment with 5-
Aza-dC. Data were normalized to the expression of Actb and values of solvent samples were set to 
the value of 1. The experiment was done three times independently, with similar outcomes. Values are 
mean ± s.d. B) FACS analysis showing enhanced expression of CD48 in 416B cells after 72 hour 
treatment with 5 M 5-Aza-dC. Data show mean ± s.d. *P  0.05.  
Furthermore, CD48 expression was found to be up-regulated on 416B cells following 
5-Aza-dC treatment (Figure 34A). Global genomic demethylation by 5-Aza-dC 
treatment was confirmed at the example of MLL-AF9 blasts (Figure 34B). 



































































Figure 34: Activation of differentiation factors after demethylation II 
A) FACS analysis showing enhanced expression of CD48 in 416B cells after 72 hour treatment with 5-
Aza-dC. Data show mean ± s.d. *P  0.05. B) Global demethylation of 5-Aza-dC treated Dnmt1+/+ 
MLL-AF9 blasts was shown using the Imprint Methylated DNA Quantification Kit. For comparison bone 
marrow (BM) cells of Dnmt1+/+ and Dnmt1 /chip mice is shown. Methylation of solvent treated MLL-AF9 
blasts was set to 100%. Data show mean ± s.d. of technical replicates. 
3.4.2 5-Aza-dC treatment causes demethylation of Gata1 and Cd48 
promoters 
To test whether the observed activation of Gata1 and CD48 expression upon 5-Aza-
dC treatment was caused by impaired silencing of the respective promoter and 
upstream regions the CpG methylation status of the treated cell lines was 
investigated. For this purpose, a MassARRAY was performed. This method allows to 
determine the CpG methylation status within a defined sequence. Thus, promoter 
sequences of Gata1 and Cd48 were analyzed applying MassARRAY technology, 
which was performed in cooperation with Sequenom, Hamburg, Germany. As 
illustrated in Figure 35, DNA methylation marks were partially removed from Gata1 
and Cd48 promoter regions. These results suggest that Gata1 and Cd48 activation 
induced by pharmacological demethylation was caused by inhibition of DNA 
methylation mediated gene silencing. 
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Figure 35: Demethylation of Gata1 and Cd48 promoters by 5-Aza-dC treatment 
Quantitative MassARRAY technology of Gata1 and Cd48 promoter sequences revealed partial 
demethylation 5-Aza-dC treatment in 416B and PU1null cells. Percentages of methylated CpGs are 
indicated.  
3.4.3 Gata1 promoter activity is methylation-dependent 
Next, I investigated the causal link between reduction of promoter CpG methylation 
and differentiation factor gene activation in more detail at the example of Gata1. For 
this purpose I applied a CpG-free luciferase construct generated in Michael Rehli’s 
laboratory [Klug and Rehli, 2006]. This vector allows to determine the effect of 
promoter methylation on reporter gene expression as only the inserted promoter 
regions contain CpG sites. Consequently, any effect based on DNA methylation is 
due to methylation changes in the investigated region. The Gata1 promoter region, 
previously described by Sergio Ottolenghi’s group [Nicolis, et al., 1991], contains 15 
CpG sites and the respective sequence was cloned in front of the luciferase reporter 
gene. The generated Gata1-luciferase construct was in vitro methylated using the 
methyltransferase Sss1 and providing the methyl group donor S-adenosylmethionine 
(SAM) to the buffer. To test for successful methylation through Sss1, a CpG 
containing control plasmid, MSCV-IRES-GFP, was processed in parallel. This 
plasmid is equipped with several restriction sites for the enzymes Hpa II and Msp I. 
While Msp I cuts DNA at its recognition sequence independent of the methylation 
status of the CpG within its recognition sequence, the methylation sensitive 
isoschizomere Hpa II cuts only in case of a not methylated CpG. The methylation 
sensitivity of this restriction enzyme system was used to test whether the control 
plasmid was successfully in vitro methylated. Figure 36A illustrates that the non-
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methylated construct is equally digested by both enzymes. If, however, the plasmid 
DNA is methylated, the methylation-sensitive Hpa II fails to cut the vector DNA. 
Having successfully tested the in vitro methylation system, the Gata1 promoter 
reporter construct was in vitro methylated and luciferase activity was measured after 
transfection into K562 cells. Luciferase activity was drastically reduced if the Gata1 
promoter sequence was methylated compared to the unmethylated control plasmid. 
These data suggest that demethylation increases Gata1 promoter activity providing a 






















































Figure 36: Gata1 promoter methylation inhibits reporter gene activity 
A) MSCV-IRES-GFP vector DNA was in vitro methylated by Sss I in the presence of S-
adenosylmethionine (SAM). In non-methylated samples Sss I treatment was performed in the absence 
of SAM. Digestion with Hpa II or Msp I demonstrated successful in vitro methylation. B) Luciferase 
assay of K562 cells transfected with in vitro methylated or unmethylated pCpGL-Gata1 promoter–
firefly luciferase construct. Firefly luciferase activity was normalized using Renilla luciferase activity as 
internal transfection control. Values are mean ± s.d.. 
3.4.4 Ectopic Gata1 expression impairs leukemia cell growth 
The results presented in the two previous sections demonstrated that 
hypomethylation can induce expression of differentiation genes such as Gata1 in 
leukemic cells. However, if such gene activation is of functional importance to 
leukemia cell growth is unclear. To address this question, I tested whether forced 
expression of Gata1 affects leukemia cell growth by retrovirally introducing Gata1 in 
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Pu1null cells. Ectopic expression of Gata1 strongly reduced growth of Pu1null cells 
compared to control cells (Figure 37). 
Taken together, demethylation induced activation of differentiation factor expression 




















Figure 37: Leukemia cell growth is impaired by ectopic Gata1 expression 
Enforced Gata1 expression reduces growth of myeloid leukemia cells. PU1null cells were transduced 
with retrovirus expressing GATA1 and GFP, or GFP only, and subjected to liquid culture. Percentage 
of GFP+ cells were evaluated by FACS over 4 consecutive days. Percentage of GFP+ cells on day 0 
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4 Discussion 
The aim of this thesis was to investigate how DNA methylation is involved in 
leukemia stem cell (LSC) function. Constitutive methylation has been shown to be 
crucial for the maintenance of hematopoietic stem cell (HSC) multipotency. Further-
more, aberrant DNA methylation is a hallmark of cancer. However, so far a functional 
link between DNA methylation and the establishment or maintenance of unique 
cancer stem cell (CSC) functions, such as unrestricted self-renewal and, in some 
cases, lineage pathway choice, was missing. In order to investigate this link, 
hypomethylated hematopoietic cells were tested in three different oncogene driven 
leukemia models and consequences of hypomethylation on LSC self-renewal and 
lineage pathway choice were investigated.  
4.1 The role of DNA methylation in LSC self-renewal and 
lineage pathway choices 
To study the role of DNA methylation in LSC fate decisions, I chose a knock-down 
mouse model of the maintenance methyltransferase Dnmt1. Other than the 
methyltransferases Dnmt3a and Dnmt3b, which act as de novo methyltransferases 
and are consequently most important for early developmental stages, Dnmt1 is the 
main methyltransferase in somatic cells. For this reason, Dnmt1 was the 
methyltransferase chosen to be manipulated in the investigations of this thesis. 
However, it should be mentioned that a recent study showed that Dnmt3a mutations 
frequently occur in myeloid leukemia, suggested that Dnmt3a might also play a role 
in leukemia development [Ley, et al., 2010]. A knockdown approach was applied to 
test Dnmt1 function in leukemia, as a complete knock-out of Dnmt1 was shown to be 
fatal based on preliminary results from our group (C. Langhans, L. Vockentanz and 
F. Rosenbauer, unpublished results) as well as previous publications. 
4.1.1 DNA methylation critically determines lineage decisions of leukemia 
initiating cells 
The first question addressed in this thesis was as to whether lineage fate decision of 
leukemia initiating cells are affected by alterations of Dnmt1 levels. In order to test 
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this, I used a leukemia model encompassing both acute myeloid and lymphoid 
leukemia. This was achieved by co-expression of the oncogene c-Myc and the anti-
apoptotic factor Bcl2, which has been shown to induce a bilinear myeloid/B-lymphoid 
leukemia in mice [Luo, et al., 2005]. Myc-Bcl2 co-expression achieved by retroviral 
gene transfer, as expected, created a bilinear leukemia with characteristics about 
identical to those described by the authors. In sharp contrast, however, Myc-Bcl2 
expressing hypomethylated cells gave rise to a purely myeloid disease. Absence of 
B-lymphoid leukemic cells was shown by FACS and morphological analysis. This 
was further on confirmed by an exclusively myeloid-specific gene expression pattern 
compared to a mixed B-lymphoid/myeloid expression pattern observed in bilinear 
leukemias. Consequently, these data suggested that lineage choices in a bi-potential 
leukemia system are determined by DNA methylation levels. Any lineage bias based 
on the lineage composition of the cell population used for initial transduction were 
ruled out by choosing not-lineage committed stem cells as a starting cell population. 
Whereas malignant B-cell development was found to be entirely blocked by low DNA 
methylation levels, hypomethylated leukemia cells occasionally ‘escaped’ into an 
alternative T-lymphoid fate as rare cases of mixed T-lymphoid/myeloid leukemias 
were observed. T-lineage affiliation of these cells was confirmed by a rearranged T-
cell receptor locus. A certain bias of hypomethylated hematopoietic cells towards T-
lymphoid neoplasia development was already shown in the publication originally 
describing Dnmt1 /chip knock-down mice. About 80% of Dnmt1 /chip mice developed 
aggressive thymic lymphomas at four to eight months of age [Gaudet, et al., 2003]. 
However, even though we did not perform large-cohort investigations of aged 
Dnmt1 /chip mice to specifically challenge or reproduce these results, we observed 
only very rare cases of leukemia development in up to one year old Dnmt1 
hypomorphic mice. Phenotypic characterization of such individual cases rather 
revealed an acute myeloid leukemia (AML)-like phenotype instead of the occurrence 
of T-cell lymphomas (data not shown). 
Given this ambivalent picture of whether hypomethylation allows or even promotes T-
lineage malignancies, I specifically tackled this question applying an oncogene driven 
T-lymphoma model. Notch1-IC, the constitutively active version of the key T-cell 
factor Notch1, was previously shown to transform hematopoietic cells into T-
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lymphoma development [Allman, et al., 2001; Pear, et al., 1996]. The transforming 
nature of Notch1-IC was successfully recapitulated in Dnmt1+/+ cells, which gave rise 
to aggressive T-cell lymphomas. On the other hand, Dnmt1 /chip cells with constitutive 
Notch1 signaling were unable to form T-ALL. These data suggest that, at least in 
case of Notch1-IC driven T-cell leukemia, hypomethylation blocked the onset T-
lineage malignancies. The observed discrepancy between a complete block of T-ALL 
in the Notch1-IC model and the occasional development of T-ALL in the Myc/Bcl2 
model can only be subject to speculations. One possibility could be that, as Myc/Bcl2 
is able to transform hypomethylated cells and create a leukemia, this model harbors 
a fully transformed leukemia initiating cell which might follow a T-lymphoid 
differentiation branch later on. However, in the Notch1-IC model a more T-cell 
specific transformation stimulus is offered to the cells and hypomethylated cells might 
not be susceptible to this in the first place.  
Taken together, DNA methylation appears to critically determine lineage fate 
decisions of leukemia stem/initiating cells. These data suggest that whereas 
malignant myeloid pathway choice is compatible with low DNA methylation levels, the 
development of lymphoid leukemias is abrogated in a hypomethylated setting. These 
observations are clearly due to cell-intrinsic hypomethylation effects as results were 
obtained from transplantation assays which provide equal wildtype-methylated micro-
environments. Cell intrinsic lineage restrictions due to hypomethylation were 
previously described in physiological hematopoiesis. Reduced Dnmt1 expression 
levels in HSCs were demonstrated to cause a block of the lymphoid differentiation 
branch including both B- and T-lymphoid cells [Broske, et al., 2009]. Additionally, 
treatment of B-cell leukemia cell lines with the demethylating agent 5-Aza-dC and the 
histone deacetylase inhibitor trichostatin A (TSA) were shown to cause a complete 
extinction of the B-cell specific expression program [Ehlers, et al., 2008]. These data 
support the fact that DNA methylation is indispensable for leukemic B-cell identity. 
As described in chapter 1.5.2, DNA methyltransferase inhibitors such as 5-
Azacytidine or 5-Aza-2’deoxycytidine are used in the treatment of hematopoietic 
malignancies. In particular, such agents are approved or in trials mainly for therapy of 
myeloid malignancies including myeloid dysplastic syndrome (MDS) and AML 
[Fenaux, 2005; Gore, 2005]. Based on the presented data, such applications might 
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also be promising for treatment of lymphoid malignancies, especially B-cell 
leukemias, as DNA methylation was shown to be essential for the development of 
these diseases. However, we have shown in previous experiments that Dnmt1 is no 
longer required for B-cell differentiation once the B-cell program has been 
established, which is in clear contrast to the evident necessity of DNA methylation for 
the launch of B-cell commitment at the stem cell level [Broske, et al., 2009]. 
Consequently, acute B-lymphoid leukemia (B-ALL) might not present a valid target 
for demethylating therapy. The question whether maintenance of B-ALL, similar to its 
initiation, relies on DNA methylation, displays an important issue, which should be 
addressed in future projects. However, an important fact which would have to be 
taken into account when conducting such investigations is the following: It has been 
shown that, depending on the nature of the transforming event for B-ALL induction 
(i.e. the choice of oncogene), the leukemia initiating stem cell origins from different 
stages of hematopoietic development, including HSCs, B-cell progenitors and 
committed B-cell progenitors [Castor, et al., 2005]. Thus, LSCs might very differently 
depend on DNA methylation to retain their stem cell functions. Consequently, 
demethylating therapy might be varyingly effective depending on the initial 
transforming event and thus on the nature of the leukemia initiating cell.  
4.1.2 DNA methylation is required for proper LSC renewal  
To address the question whether self-renewal capacities of LSCs are affected by 
DNA methylation levels, I applied an acute myeloid leukemia (AML) model achieved 
by forced expression of the oncogenic fusion gene MLL-AF9. First, I conducted in 
vitro colony-formation assays, which allow a first estimation of leukemic trans-
formability and self-renewal potential. MLL-AF9 transduced hypomethylated cells 
showed severely reduced replating capacity compared to MLL-AF9 transduced 
wildtype cells. This data allowed the assumptions that reduced levels of DNA 
methylation diminish the capacity of hematopoietic cells to be immortalized by the 
MLL-AF9 oncogene and to (re)gain unrestricted self-renewal reflected by unlimited 
replating capacity.  
To test this assumption in an in vivo experiment, MLL-AF9 driven AML development 
was investigated in an inducible Dnmt1 knockdown model, which allowed to 
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circumvent any experimental bias due to unequal engraftment capacities of 
hypomethylated cells. AML developed from transformed hypomethylated cells and, 
whereas the phenotype of these leukemias was unchanged compared to control 
leukemias, they displayed drastic differences in disease latencies, which confirmed 
results gathered in the replating assays. Furthermore, limiting dilution experiments 
were conducted to specifically test self-renewal capacities of Dnmt1 /chip leukemia 
cells. Control leukemias (Dnmt1lox/chip) were determined to posses an LSC frequency 
of to 1 in 91. These results were in line with data published by Scott Armstrong’s 
group, as based on their results, obtained in limiting dilution experiments with MLL-
AF9 leukemic bone marrow cells, an LSC frequency of 1 in 126 could be calculated 
[Krivtsov, et al., 2006]. In contrast to the number calculated from control leukemias , 
hypomethylated leukemias displayed an LSC frequency of 1 in 1,072 cells. 
Consequently, Dnmt1 hypomorphic leukemias revealed an 11.8-fold decrease in 
cells, which are able to initiate leukemia in a secondary recipient thus, by definition, 
display functional LSC. The fact that prolonged latencies were in deed caused by 
less functional LSCs was further underlined by the observation that hypomethylated 
MLL-AF9 blasts displayed equal proliferation rates during in vitro culture compared to 
wildtype counterparts suggesting that leukemia bulk growth is rather unaffected by 
DNA hypomethylation. 
Non-inducible, direct knockdown (Dnmt1 /chip) MLL-AF9 leukemias were generated 
for further experiments which aimed at the more detailed analysis of the LSC 
compartment. I reasoned this switch of mouse models necessary as few leukemic 
cells which had escaped cre-mediated Dnmt1 depletion overgrew hypomethylated 
leukemias due to selection advantages. Confirming previous results presented here, 
development of Dnmt1 /chip leukemias was again marked by significantly prolonged 
latency times. An LSC-enriched cell population, defined by strong expression of the 
surface marker c-Kit was isolated from leukemias according to previous descriptions 
[Somervaille, et al., 2009]. Enrichment of cells with LSC identity in the c-Kithigh cells 
was confirmed in both hypomethylated as well as in control leukemias by clearly 
enhanced colony-forming ability as compared to c-Kit non-expressing cells. 
Functional testing of leukemic self-renewal of hypomethylated c-Kithigh cells in serial 
replating assays revealed a progressive loss of cells with self-renewal potential within 
this cell pool. In contrast to that, wildtype c-Kithigh cells were able to maintain a 
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constant level of self-renewing colony-forming cells.  
These results were furthermore underlined by in vivo experiments. To compare the 
leukemia initiating potential of Dnmt1 /chip and Dnmt1+/+ MLL-AF9 c-Kithigh cells these 
cells were subjected to a limiting dilution experiment. With a calculated LSC 
frequency of 1 in 33 in Dnmt1+/+ c-Kithigh cells, the frequency of cells capable of 
initiating a leukemia was about three-fold increased in the LSC-enriched cell 
population. Dnmt1 /chip c-Kithigh cells, however, displayed an LSC frequency of 1 in 
478, confirming a clearly diminished number of LSCs due to hypomethylation. 
Importantly, colony numbers in serial replating assays were comparable on the first 
plate where freshly isolated, ex-vivo c-Kithigh leukemia cells were seeded. These data 
would argue that the number of colony forming cells in a terminal leukemia, being a 
measure for the LSC frequency, is actually similar, as it has been shown previously 
that expanded cell pools originating from a single colony are able to initiate leukemia 
development after transplantation [Somervaille and Cleary, 2006]. Consequently, one 
might speculate that hypomethylated leukemias might actually posses a comparable 
number of LSCs, which, however, are deficient in self-renewal capacity accounting 
for drastically diminished leukemia-forming capacity. To investigate this further, one 
could expand single Dnmt1 /chip colonies and test whether these cells are able to form 
leukemia upon transplantation. If so, this would point to the conclusion that 
decreased leukemia formation due to hypomethylation is caused by restricted self-
renewal and/or proliferative capacities of individual transplanted LSCs in the 
recipient.  
4.1.3 Hypomethylated bone marrow environment does not affect leukemia 
development 
Contrasting the severe cell intrinsic effects of DNA methylation on LSC functions, the 
methylation status of the bone marrow microenvironment was shown not to be critical 
for MLL-AF9 LSC functioning. Wildtype leukemias developed equally, both regarding 
phenotype as well as leukemia-latency, independent of being surrounded by 
hypomethylated and physiologically methylated stroma cells. This issue was 
important to be investigated as hypomethylation effects of bone marrow stroma cells 
on leukemia cells have to be thoroughly taken into account regarding the 
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therapeutical use of DNMT inhibitors, as the microenvironment is equally exposed to 
these drugs as the hematopoietic/ leukemic cells. Moreover, cell-to-stroma 
interactions have been shown to be crucial for the development of leukemia. The 
phenotype of human MLL-AF9 leukemia cells was shown to be dependent on the 
stroma-cell cytokine-producing characteristics of the recipient mice [Wei, et al., 2008]. 
The absence of hypomethylated niche effects on leukemia fates presented here are 
in line with data from experiments conducted in our lab concerning the impact of 
reduced DNA methylation on normal hematopoiesis. We found that wildtype 
hematopoietic donor cells equally repopulated both Dnmt1-knockdown and Dnmt1+/+ 
recipient mice both in regard to general engraftment capacities as well as lineage 
composition (unpublished data). In conclusion, whereas both leukemic as well as 
hematopoietic stem cells are greatly impacted by cell-intrinsic loss of DNA 
methylation, no obvious effects on their function could be observed as a 
consequence to microenvironmental hypomethylation. 
4.1.4 Differentiation factors induced by pharmacological demethylation 
inhibit leukemia growth 
Studies on the role of DNMT1 in hematopoiesis using a genetic knockdown of Dnmt1 
(Dnmt1 /chip) revealed that hypomethylated HSCs display an altered gene expression 
pattern, which is more akin to a myeloerythroid progenitor signature rather that a 
stem cell signature. This up-regulation of myeloerythroid-specific factors, which HSCs 
are usually devoid of, was shown to result in impaired stem cell self-renewal [Broske, 
et al., 2009]. These observations raised the possibility that treatment of cancer cells 
with demethylating agents might be able to activate expression of differentiation 
factors, which might ultimately lead to a reduction of malignant growth. Additionally 
supportive of this hypothesis is the fact that hematopoietic differentiation factors such 
as Id2 and Cebp  had earlier been shown to be silenced by methylation in cancer 
cells [Flotho, et al., 2009; Hackanson, et al., 2008]. Indeed, I could show that 5-Aza-
dC treatment of different myeloid cell lines and primary leukemia cells was followed 
by an up-regulation of the differentiation factors Gata1 and CD48. The observed up-
regulation was paralleled by a loss of promoter methylation at the respective gene 
loci. Thus, demethylating agents are able to revert the DNA methylation mediated 
gene silencing of factors repressed in cancer cells. A direct link to DNA methylation 
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dependent gene regulation was shown at the example of Gata1. Methylation of the 
region upstream of the Gata1 transcriptional start site was shown to drastically 
reduce gene expression in a luciferase reporter assay compared to the non-
methylated upstream region. Biological significance for enhanced differentiation 
factor expression on leukemic proliferation was directly proven by ectopic expression 
of Gata1 in transformed myeloid Pu1null cells. Reduced cell growth in Gata1 
expressing cells compared to control cells suggested that induced differentiation by 
these factors interferes with leukemic cell renewal and/or proliferation. Taken 
together, pharmacological demethylation is able to counteract the methylation 
mediated gene silencing of differentiation factors. Elevated expression of such 
factors, in turn, inhibits neoplastic growth, consequently displaying an interesting 
approach to interfere with leukemia stem cell self-renewal. 
DNA methylation is known to be tightly interconnected with histone modification 
mechanisms. This interconnectedness is known to act in a bi-directional manner. For 
example de novo DNA methyltransferases are known to be specifically recruited to 
loci which already display repressive histone marks. On the other hand it has been 
shown that histone modifying enzymes are recruited to DNA methylated loci [Cedar 
and Bergman, 2009]. Consequently, it might be interesting to thoroughly investigate 
DNA (de-)methylation dependent histone modifications occurring in cancer cells. 
Detailed understanding of epigenetic events in cancer cells can be of great value in 
the development of more advanced epigenetics treatment strategies. 
4.2 Conclusions and model 
Summarizing the results presented in this thesis, I propose a model depicted in 
Figure 38, which illustrates the role of DNA methylation for LSC function and 
multipotency. This model suggests that normal stem cells, here represented by 
HSCs, and cancer stem cells, here represented by LSCs, share similar methylation 
dependent control mechanisms to exercise common functional properties [Broske, et 
al., 2009; Vockentanz, et al., 2010].  
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Figure 38: Distinct DNA methylation dosage requirements of leukemia stem cells 
Leukemia stem cells (LSCs) display specific DNA methylation dosage requirements for different 
cellular programs, which is in analogy to the role of DNA methylation in hematopoietic stem cell (HSC) 
function. Leukemic stem cell self-renewal and the establishment of a neoplastic lymphoid pathway 
program depend on high levels of DNA methylation. Myeloerythroid programming of LSCs and HSCs, 
on the other hand, is feasible with low cellular dosages of DNA methylation. A certain minimal level of 
DNA methylation, however, is required to prevent apoptosis in HSCs and assumingly also in LSCs. 
Leukemic transformation, the process of equipping (stem) cells with uncontrolled self-renewal 
capacities, relies on high levels of DNA methylation [Vockentanz, et al., 2010]. 
Specifically, I found that certain programs in the functional repertoire of LSCs rely on 
high levels of DNA methylation to be properly fulfilled. This includes the initial 
transformation process, the maintenance of malignant stem cell self-renewal as well 
as commitment to the lymphoid lineage. Similar requirements have been stated for 
HSC self-renewal and lymphoid pathway choice [Broske, et al., 2009]. A further 
parallel is found in the fact that low DNA methylation levels suffice for myeloerythroid 
programming. Moreover, first results (not shown here) and previously published data 
hint towards the fact that a minimal level of DNA methylation is indispensable for 
LSCs survival as it has been shown HSC survival. Additionally, the premature 
activation of myeloerythroid differentiation factors due to missing methylation 
mediated gene silencing, which was found to be responsible for restricted capacities 
of hypomethylated HSCs, was demonstrated to display a valid mode of action to 
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inhibit malignant growth by pharmacological demethylation. 
In summary, the experiments presented in this thesis demonstrated that DNA 
methylation is critical for the capacity of LSCs to exert multi-lineage fate programs, 
which raises the hypothesis that retention or re-establishment of stem cell-specific 
methylation patterns may be an important step in the development and function of 
LSCs. 
4.3 Perspectives 
The results gathered in this thesis provide a general picture of the role of DNA 
methylation in CSCs or, more specifically, in LSCs. However, it is still unresolved 
which gene programs promoting leukemic self-renewal are controlled by DNA 
methylation. This question is subject of a future project in this group, which aims at 
pinpointing epigenetically regulated genes which are crucial for cancer self-renewal. 
For this purpose LSCs from hypomethylated and control leukemias will be analyzed 
by global mRNA sequencing. This method will allow an in depth insight into the trans-
criptional regulation of LSCs by DNA methylation. Besides the crucial information on 
the methylation dependent regulation of “leukemia self-renewal genes”, this analysis 
might furthermore detect new surface markers which are present on hypomethylated 
stem cells. Such a discovery would be of great interest from a therapeutical point of 
view, as surface markers are a valuable target for anti-cancer therapy by therapeutic 
antibodies. A surface marker present on hypomethylated tumor stem cells but not on 
the normal tissue stem cells might be a promising approach for a combinatorial 
cancer treatment encompassing demethylating drugs and specifically tailored 
antibody therapy. 
In conclusion, for development of novel therapeutic strategies specifically targeting 
cancer stem cells, it is inevitable to understand the molecular basics of how these 
cells acquire and maintain unlimited self-renewal potential. As this work demon-
strated a crucial role for DNA methylation in these processes, a detailed under-
standing of methylation mediated control of self-renewal programs displays an 
important step for the development of cancer stem cell targeted therapy. 
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Aa amino acid 
AGM aorta-gonad-mesonephros region 
ALL acute lymphoid leukemia 
AML acute myeloid leukemia 
APC allophycocyanin or adenomatous polyposis coli 
bcl-2 B-cell lymphoma 2 
BCR B cell receptor 
BM bone marrow 
bp base pair 
BSA bovine serum albumin
C cytosine 
CD cluster of differentiation 
C/EBP CCAATT/enhancer binding protein 
CLP common lymphoid progenitor 
CMP common myeloid progenitor
csf1r colony stimulating factor 1 receptor 
c-Myc myelocytomatosis viral oncogene homolog 
CpG cytosine guanine dinucleotide 
Cre cyclization recombination protein 
CSC cancer stem cell 
Csf2r  (=Gm-csfr) granulocyte/macrophage stimulating factor receptor 
CTCF CCCTC-binding factor 
DAPI 4’,6-diamidino-2-phenylindole
DMEM Dulbecco’s modified Eagle medium 
DMSO dimethylsulfoxid
DNA desoxyribonucleic acid
dNTP deoxynucleotide triphosphate 
DTT dithiotreitol 
E embryonic day 
e.g. exempli gratia 
Ebf1 early B cell factor 1 
EDTA ethylenediaminetetraacetate
Env  envelope protein 
EPO erythropoietin  
ES cells embryonic stem cells 
EZH2 enhancer of zeste homolog 2 
FACS fluorescent activated cell sorting 
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FCS fetal calf serum 
FITC fluoresceinisothiocyanat 
FL fetal liver 
Flt3 Fms- related tyrosine kinase 3 
Flt3L Flt3 ligand 
fw forward 
g gravity 
GMP granulocyte-macrophage precursor 
G/M-CSF granulocyte/macrophage stimulating factor 
G9A also known as EHMT2 euchromatic histone-lysine N-methyltransferase 2 
Gadd45 growth arrest and DNA damage 
Gag-pol group antigen protein - polymerase 
Gata1 GATA binding protein 1 or globin transcription factor 1 




HP1 heterochromatin protein 1 
HSC hematopoietic stem cell 
ICF immunodeficiency, centromeric instability and facial anomalies syndrome 
Ig immunoglobulin 
Igf2 insulin-like growth factor 2 
IL interleukin 
IRES internal ribosomal entry site 
Kb kilobase 
KCl potassium chloride 
KH2PO4 potassium phosphate monobasic 
Lif leukemia inducing factor 
Lin lineage 
LN lymph node 
LOH loss of heterozygosity 
LSC leukemia stem cell 
M molar 
MBP Methyl-CpG-binding proteins 
MBD Methyl-CpG-binding domain 
MDS myelodysplastic syndrome 
MEM modified Eagle’s Medium 
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Mk megakaryocyte/ megakaryocytic 
ml millilitre 
MLL mixed lineage leukemia




MP myeloid progenitor 
MPP multi-potent progenitor 
mRNA messenger ribonucleic acid
Mx1 myxovirus (influenza virus) resistance 1 
n number 
Na2HPO4 Sodium phosphate dibasic 
NaCl Sodiumchloride 
Nk natural killer 
NLS nuclear localization sequence 
P probability value 
Pax5 paired box gene 5  




PI propidium iodide 
Pol polymerase 
Polybrene hexadimethrine bromide
pSP para-aorta splanchnopleura 
P/S penicillin/streptomycin 
rev reverse 
RNA ribonucleic acid 
rpm rotations per minute
RT room teperature 
RT-PCR reverse transcription real time polymerase chain reaction 
s.d. standard deviation 
SAM S-adenosylmethionin  
SCF stem cell factor 
SDS Sodiumdodecylsulfat 
T thymidine 
T4 T4 DNA polymerase 
TAE Tris/acetate/EDTA buffer 
Taq Taqman DNA polymerase 
TE Tris/EDTA 
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TPO thrombopoietin 
TSG tumor suppressor gene 
tRNA transfer RNA 
UV Ultraviolet 
V Volt 
WT wild type 
X X chromosome 
YFP enhanced yellow fluorescent protein 
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